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Dissecting the Novel Roles of TRIM56 in Antiviral Innate Immunity
Abstract
The tripartite motif-containing (TRIM) proteins have emerged as a new class of host antiviral restriction
factors, with several demonstrating roles in regulating innate antiviral responses. Of >70 known TRIMs,
TRIM56 inhibits replication of bovine viral diarrhea virus, a ruminant pestivirus of the family Flaviviridae,
but has no appreciable effect on VSV, a rhabdovirus. We have also shown that TRIM56 forms a complex
with the Toll-like receptor-3 (TLR3) adaptor, TRIF, via its C-terminal residues 621-750, and augments
TLR3-mediated interferon (IFN) induction and establishment of an antiviral state. Yet, TRIM56’s antiviral
spectrum and the precise underlying mechanisms by which TRIM56 executes its direct antiviral functions
and modulates TLR3 signaling remain undefined. Also unclear are the molecular determinants governing
the direct and indirect antiviral activities of TRIM56.
Herein, in Chapter 3, I show that TRIM56 poses a barrier to infections by yellow fever virus (YFV), dengue
virus serotype-2 (DENV2), and human coronavirus virus (HCoV)-OC43. Moreover, I demonstrate that
TRIM56’s anti-flavivirus effects required both the E3 ligase activity that lies in the N-terminal RING domain
and the integrity of its C-terminal portion, while the restriction of HCoV-OC43 relied upon the TRIM56 E3
ligase activity alone. Furthermore, TRIM56 was revealed to impair YFV and DENV2 propagation by
suppressing intracellular viral RNA accumulation but to compromise HCoV-OC43 infection at a later step
in the viral life cycle, suggesting that distinct TRIM56 domains accommodate differing antiviral
mechanisms. Next, in Chapter 4, I show TRIM56 puts a check on replication of influenza A and B viruses
in cell culture. Interestingly, the anti-influenza activity was independent of the E3 ligase activity, B-box, or
coiled-coil domains. Rather, deletion of a 63-residue long, C-terminal tail portion of TRIM56 abrogated the
antiviral function. Moreover, expression of this short C-terminal segment curtailed the replication of
influenza viruses as effectively as that of full-length TRIM56. Mechanistically, TRIM56 was found to
specifically impede intracellular influenza virus RNA synthesis. Altogether, TRIM56 is a versatile antiviral
host factor that confers resistance to YFV, DENV2, HCoV-OC43 and influenza viruses through overlapping
and distinct molecular determinants. Last, in Chapter 5, I report TRIM56 over-expression promoted
activation of NF-κB following TLR3 engagement but not that induced by TNF-α- or IL-1β. Next, I observed
that the coiled-coil domain and residues 431-610, but not the B-box or residues 355-433, were required for
TRIM56 augmentation of TLR3-dependent IFN-β promoter activation. Furthermore, alanine screening
mutagenesis suggested the S469A+S471A+S475A triple mutant and S471A, S475A and S710A single
mutant failed to enhance TLR3 signaling. In line with this, S471A, S475A and S710A, as well as the coiledcoil deletion mutant lost the ability to enhance poly-I:C-mediated establishment of an antiviral state
compared with wild-type TRIM56. Collectively, these data reveal novel insights into the mechanism of
TRIM56 augmentation of TLR3-dependent antiviral response and highlight a role for TRIM56 scaffolding
and phosphorylation in positive regulation of TLR3 signaling.
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ABSTRACT
The tripartite motif-containing (TRIM) proteins have emerged as a new class of host
antiviral restriction factors, with several demonstrating roles in regulating innate antiviral
responses. Of >70 known TRIMs, TRIM56 inhibits replication of bovine viral diarrhea
virus, a ruminant pestivirus of the family Flaviviridae, but has no appreciable effect on
VSV, a rhabdovirus. We have also shown that TRIM56 forms a complex with the Tolllike receptor-3 (TLR3) adaptor, TRIF, via its C-terminal residues 621-750, and augments
TLR3-mediated interferon (IFN) induction and establishment of an antiviral state. Yet,
TRIM56’s antiviral spectrum and the precise underlying mechanisms by which TRIM56
executes its direct antiviral functions and modulates TLR3 signaling remain undefined.
Also unclear are the molecular determinants governing the direct and indirect antiviral
activities of TRIM56.
Herein, in Chapter 3, I show that TRIM56 poses a barrier to infections by yellow
fever virus (YFV), dengue virus serotype-2 (DENV2), and human coronavirus virus
(HCoV)-OC43. Moreover, I demonstrate that TRIM56’s anti-flavivirus effects required
both the E3 ligase activity that lies in the N-terminal RING domain and the integrity of its
C-terminal portion, while the restriction of HCoV-OC43 relied upon the TRIM56 E3
ligase activity alone. Furthermore, TRIM56 was revealed to impair YFV and DENV2
propagation by suppressing intracellular viral RNA accumulation but to compromise
HCoV-OC43 infection at a later step in the viral life cycle, suggesting that distinct
TRIM56 domains accommodate differing antiviral mechanisms. Next, in Chapter 4, I
show TRIM56 puts a check on replication of influenza A and B viruses in cell culture.
Interestingly, the anti-influenza activity was independent of the E3 ligase activity, B-box,
or coiled-coil domains. Rather, deletion of a 63-residue long, C-terminal tail portion of
TRIM56 abrogated the antiviral function. Moreover, expression of this short C-terminal
segment curtailed the replication of influenza viruses as effectively as that of full-length
TRIM56. Mechanistically, TRIM56 was found to specifically impede intracellular
influenza virus RNA synthesis. Altogether, TRIM56 is a versatile antiviral host factor
that confers resistance to YFV, DENV2, HCoV-OC43 and influenza viruses through
overlapping and distinct molecular determinants. Last, in Chapter 5, I report TRIM56
over-expression promoted activation of NF-κB following TLR3 engagement but not that
induced by TNF-α- or IL-1β. Next, I observed that the coiled-coil domain and residues
431-610, but not the B-box or residues 355-433, were required for TRIM56 augmentation
of TLR3-dependent IFN-β promoter activation. Furthermore, alanine screening
mutagenesis suggested the S469A+S471A+S475A triple mutant and S471A, S475A and
S710A single mutant failed to enhance TLR3 signaling. In line with this, S471A, S475A
and S710A, as well as the coiled-coil deletion mutant lost the ability to enhance poly-I:Cmediated establishment of an antiviral state compared with wild-type TRIM56.
Collectively, these data reveal novel insights into the mechanism of TRIM56
augmentation of TLR3-dependent antiviral response and highlight a role for TRIM56
scaffolding and phosphorylation in positive regulation of TLR3 signaling.
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CHAPTER 1.

INTRODUCTION

Background
TLR3-mediated Innate Immune Responses against Positive-strand RNA Viruses
In response to viral invasion, the innate immune system plays a critical role in
recognizing intruding viral pathogens and inducing antiviral or inflammatory responses,
thereby facilitating adaptive immune responses (1-4). Among the multilayered
mechanisms of host intrinsic defense, germline-encoded pattern recognition receptors
(PRRs) present on innate immune sentinel cells, such as Toll-like receptors (TLRs) and
retinoic-inducible gene-I (RIG-I)-like receptors, play important parts in sensing viral
nucleic acids or replicative intermediates produced during viral replication as a major
class of viral pathogen-associated molecular pattern (PAMP). Those receptors initiate
downstream intracellular signaling cascades that culminate in the production of
interferons (IFNs) and pro-inflammatory cytokines/chemokines. Therefore, the innate
immune responses constitute a primary and fundamental component of host defense in
the immediate-early phase of viral infections (2-5).
Among various host PRRs, TLRs represent the first type to be discovered and
characterized. There are 10 human TLRs (TLR1-TLR10) and 12 murine TLRs (TLR1-9
and TLR11-13) (4). Structurally speaking, all TLRs are type I transmembrane proteins
consisting of N-terminal leucine-rich repeat-containing ectodomain which interacts with
and recognizes PAMPs, a transmembrane domain, and a C-terminal Toll-interleukin-1
receptor (IL-1R) homology (TIR) domain which is responsible for activation of signaling
transduction via interacting with their adaptor proteins (1,2,4). There are only two types
of adaptors for TLRs-mediated signal transduction – either myeloid differentiation
primary response 88 (MyD88) or TIR-domain-containing adaptor inducing interferon-β
(TRIF) (4). Remarkably, TLR3 only signals through TRIF while the other TLRs signal
through MyD88, with TLR4 using both adaptors. TLRs also vary on cellular localization
and the ligands (PAMPs) to be sensed (4). For example, TLR2 and TLR4 on the cell
surface are responsible for recognition of viral proteins. TLR3, TLR7, TLR8 and TLR9
localized in endosomes sense intracellular viral nucleic acids (1). Specifically, TLR3,
TLR7/TLR8 and TLR9 recognize viral dsRNA, ssRNA and unmethylated CpG DNA,
respectively. Engagement of TLRs with their cognate ligands activates distinct,
intracellular signaling pathways through the adaptor proteins, which relay signals to
downstream IκB (IKK) and IKK-related kinases (2-4). Subsequently, the classical IKKs
(IKKα/IKKβ/IKKγ) activate the transcription factor NF-κB for downstream proinflammatory cytokine production, while the IKK-related kinases (TBK1/IKKε)
phosphorylate and activate IFN-regulatory factors IRF3 and/or IRF7 which are critical
for induction of type I IFNs (IFN-β and IFN-α). IFNs further induce hundreds of IFNstimulated genes (ISGs) to establish an antiviral state restricting viral propagation and
dissemination (1-4).

1

Among different TLRs, TLR3 represents the first one to be well characterized which
senses nucleic acid, i.e., dsRNA, and TLR3 as an essential PRR has been demonstrated to
play important roles in sensing and fending off positive-strand RNA viruses (1,2,4). For
instance, TLR3 is able to sense the infection by dengue virus and plays a protective role
against West Nile Virus infection (6,7). TLR3 signaling also has a protective effect on the
heart after encephalomyocarditis virus-induced injury and decreases the virulence of this
picornavirus (8). However, facing the host innate immune system, numerous viruses have
evolved to acquire different strategies to circumvent or counteract with the TLRdependent host defense responses (4). For instance, vaccinia viruses encode two proteins,
A46R and A52R, which associate with TLR adaptor proteins and TRAF6, respectively,
thereby blocking TLR signaling (9,10). Another appealing example is hepatitis C virus
which utilizes its NS3/4A serine protease to cleave TRIF, the sole adaptor for TLR3, to
compromise TLR3-mediated host antiviral immunity (11).
Host Responses to Influenza Virus Infection
Classified within the family Orthomyxoviridae, influenza A and B viruses (IAV and
IBV) are important respiratory pathogens responsible for significant morbidity and
mortality worldwide (12-15). Apart from typical influenza diseases, influenza virus
infection may trigger severe influenza-related complications, for instance, cardiovascular
diseases (CVDs) (12,13). This is especially true for the elderly who represents an
overlapping high-risk population for both influenza virus infections and CVDs (16-18).
Remarkably, epidemiological studies have established an association of IAV infection
with CVDs (16-18). Influenza viruses primarily infect lungs and respiratory tract but can
trigger cardiac complications, such as atherosclerosis and acute myocardial infarction
(16-18). Influenza vaccines are commonly considered to be an effective measure to
prevent influenza infection. However, despite its protective effects shown on some CVD
patients, influenza vaccine efficacy declines with age: from approximately 59% in adults
aged 18-65 years to 49% in the 65+ population (19). What’s worse, the elderly with
underlying CVDs are particularly vulnerable to unanticipated new influenza subtypes that
emerge. These issues underscore the importance of developing novel and broad-spectrum
anti-influenza approaches to provide high-risk populations with better CVD prevention
(18,19).
Influenza viruses are characterized by segmented, negative-strand RNA genomes in
the viral particle core, which are encapsidated by nucleoprotein (NP) and bound with
polymerase proteins, thus forming viral ribonucleoprotein (vRNP) complexes (15,20,21).
Influenza virus life cycles are featured by the dependence on nuclear functions, which is
rare to RNA viruses (15). After cell entry, trafficking of the viral genome into the nucleus
is an active process dependent on the nuclear import machinery. Although the major viral
components of IAV vRNP complexes all possess nuclear localization sequences (NLSs),
the signals on NP are believed to be both sufficient and necessary for recognition and
pick-up by cellular importins (15,20,21). Among the localization signals, the strongest
unconventional NLS-1 of NP is found at its extreme N-terminus, a weaker, bipartite
NLS-2 is present in the middle of NP (residues 198-216), and a nuclear accumulation
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sequence (NAS) has been detected at the C-terminus (residues 336-345). These NLSs on
NP are also important for nuclear import of this viral protein after translation (15,20,21).
In response to influenza invasion, the innate immune system represents a front line of
host defense armed with multi-layered mechanisms. Of these, PRRs such as TLRs and
RIG-I-like receptors, sense viral nucleic acids, a major class of viral PAMPs triggering
intracellular signaling pathways that activate IRF3 and NF-κB, which play pivotal roles
in the production of IFNs and pro-inflammatory cytokines/chemokines (22-24). Influenza
virus, in return, inhibits IRF3 activation by its non-structural protein (NS)-1 to decrease
IFN generation whereas it exploits activated NF-κB to regulate its viral RNA (vRNA)
synthesis, develop inflammation and induce synthesis of ectopic trypsins and matrix
metalloproteinases (MMPs), thereby triggering cardiac injuries (22-26). IAV structural
proteins, e.g. NP, can also augment NF-κB signaling, the molecular mechanisms
underlying which remain elusive (27).
TRIMs: Novel Players in Antiviral Innate Immunity
The tripartite motif-containing (TRIM) protein family consists of more than 70
members in human beings. It is previously known that TRIMs play essential roles in a
broad array of biological processes, including proliferation, differentiation and apoptosis.
Over the past decade, people have begun to appreciate important roles of TRIM family
members in antiviral innate immunity (28-30). As suggested by their names, there are
three highly conserved domains in TRIMs’ N-terminal RBCC motif, including RING,
one or two B-boxes and coiled-coil domains. In contrast, TRIMs C-terminal tails vary
with different domains, based on which this protein family can be divided into 11
subfamilies (Figure 1-1) (31). Functionally speaking, thanks to the RING domains,
TRIMs have been believed to be a large group of E3 ubiquitin (Ub) ligases. The B-box
domains of TRIMs are regarded as zinc-binding motifs while coiled-coil domains play
important roles in self-association and oligomerization of TRIM molecules, thereby
acting as scaffolds to recruit and form multi-protein signaling complexes (28-31).
Roles of TRIMs in restriction of retroviruses are the first to be characterized, as
exemplified by TRIM5α which suppresses HIV-1 multiplication by catalyzing polyubiquitination of the viral capsid and blocking the viral uncoating step (28-31). A
growing number of TRIMs have been progressively found to play direct antiviral roles in
host restriction of viruses of other families by targeting important steps in the viral life
cycle (Figure 1-2) (28-32). For example, TRIM22 polyubiquitinates IAV NP and targets
it for proteasome-dependent degradation (33). In addition, TRIM56 was identified as a
pleiotropic host antiviral factor restricting distinct RNA viruses via overlapping and
distinct molecular determinants, including human coronavirus-OC43, IAV and
Flaviviridae members (34-36).
Intriguingly, some TRIMs are also able to positively or negatively modulate the
innate antiviral immune signaling pathways, thereby impacting IFN induction. On one
hand, it is reported that approximately more than 30 TRIMs act at multiple levels of
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Figure 1-1. TRIM family members and their subfamily classification.
TRIM protein family members can be divided into up to 11 subfamilies based on the
diversity of their C-terminal domain composition.
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Figure 1-2. Roles of TRIMs in innate antiviral immunity.
(Left) TRIMs exhibit direct antiviral activity by targeting important steps of the viral life
cycle. TRIM1/8/11/31 inhibit viral entry step. TRIM5α prevents uncoating step of HIV-1.
TRIM11/22/28/32 suppress retroviral gene transcription. TRIM56 restricts intracellular
viral RNA replication of Flaviviridae members and influenza viruses. TRIM11/22/26/32
block virus packaging/release steps. (Right) TRIMs play important roles in modulation of
PRR-mediated innate immune signaling pathways. TRIM25 ubiquitinates and activates
RIG-I, thereby promoting IFN induction. TRIM56 potentiates TLR3 signaling by
forming a complex with TRIF, the adaptor for TLR3. TRIM27 inhibits IKK activation.
TRIM21/28 down-regulate IRF7 activation.
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innate immune signaling pathways to enhance antiviral responses (37). A prime example
among this group of TRIMs is E3 ligase TRIM25 which substantially augments RIG-Imediated signaling pathway and IFN production by ubiquitinating and activating RIG-I
(38). Another example is TRIM56, which has been demonstrated to significantly enhance
TLR3-mediated signaling and establishment of an antiviral state by forming a complex
with TRIF (39). On the other, a handful of TRIMs have been identified as negative
regulators of PRR signaling, such as TRIM21 and TRIM27 down-regulating IKK activity
and IRF7 activation, respectively (29,30).
Statement of Purpose
The tripartite motif-containing (TRIM) proteins have emerged as a new class of host
antiviral restriction factors, with several demonstrating roles in regulating innate antiviral
responses. Of >70 known TRIMs, TRIM56 inhibits replication of bovine viral diarrhea
virus, a ruminant pestivirus of the family Flaviviridae, but has no appreciable effect on
VSV, a rhabdovirus. We have also shown that TRIM56 forms a complex with the Tolllike receptor-3 (TLR3) adaptor, TRIF, via its C-terminal residues 621-750, and augments
TLR3-mediated interferon (IFN) induction and establishment of an antiviral state. Yet,
TRIM56’s antiviral spectrum and the precise underlying mechanisms by which TRIM56
executes its direct antiviral functions and modulates TLR3 signaling remain undefined.
Also unclear are the molecular determinants governing the direct and indirect antiviral
activities of TRIM56. The goal of this dissertation research has been to dissect the
molecular determinants dictating TRIM56’s novel antiviral activities against positiveand negative-strand RNA viruses and TRIM56-mediated positive regulation of the TLR3
antiviral signaling pathway as well as the molecular mechanisms by which TRIM56
executes its direct antiviral and signaling regulation functions.
x

The objective of Chapter 3 is to dissect the molecular determinants dictating
TRIM56’s novel antiviral activities against medically important, positive-strand
RNA viruses and the molecular mechanisms by which TRIM56 executes its direct
antiviral functions against these viruses.

x

The objective of Chapter 4 is to study the molecular determinants dictating
TRIM56’s novel antiviral activities against negative-strand RNA viruses and the
molecular mechanisms by which TRIM56 exhibits its direct antiviral activities
against these viruses.

x

The objective of Chapter 5 is to investigate the molecular determinants dictating
TRIM56-mediated positive regulation of the TLR3 antiviral signaling pathway
and the molecular mechanisms by which TRIM56 executes its signaling
regulation functions.
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CHAPTER 2.

METHODS AND MATERIALS1
Plasmids

To construct C-terminally V5-tagged mouse TRIM56 (here referred to as mTRIM56
or mT56) expression vector (designated pEF6-mTRIM56-V5His), the cDNA encoding
mTRIM56 was amplified by PCR using the primers 5’GAAGATCTATGAACTCCAAAGACTCCTCCCCAAC-3’ (forward) and 5’GAATTCGCTGTCAGGAAACCTGACCCTAAAGA-3’ (reverse), and subsequently
ligated into pEF6/V5-His TOPO (Invitrogen). The plasmid encoding N-terminal 2×HAtagged human TRIM56 in the pcDNA5/FRT/TO backbone (Invitrogen) has been
described previously and designated as pcDNA5/FRT/TO-HA-TRIM56 (39). Plasmid
vectors encoding various mutant (Mut) forms of TRIM56 were constructed from
pcDNA5/FRT/TO-HA-TRIM56 by QuikChange site-directed mutagenesis (Stratagene).
The vectors encoding C-terminally V5-tagged wild-type (WT) TRIM56 (designated
pcDNA3.1-TRIM56-V5His) and its E3 ligase-null mutant (Mut) CC21/24AA and various
deletion mutants were described elsewhere (34). S469A, S471A, S475A, S710A or
S710D single mutation, or S469A+S471A+S475A triple mutations were introduced into
pcDNA3.1-TRIM56-V5His, and S689A into pEF6-mTRIM56-V5His by inverse PCR.
The mutagenesis primers used are listed in Table 2-1. The gene fragments containing
mutant TRIM56 (S469A, S471A, S475A, S710A, S710D or S469A+S471A+S475A) in
pcDNA3.1 backbone were then swapped to pcDNA5/FRT/TO-HA backbone (Invitrogen)
and the resultant vectors were designated pcDNA5/FRT/TO-HA-TRIM56 Mut. The
coding sequences of the C-terminal-tail 135 and 63 residues (CTT135 and CTT63) of
TRIM56 were amplified from a plasmid encoding full-length human TRIM56 via PCR
and subsequently ligated into the pcDNA5/FRT/TO (Invitrogen) vector to generate the
pcDNA5/FRT/TO-HA-TRIM56-CTT135 and -CTT63 constructs, respectively. In these
constructs TRIM56-CTT135 and CTT63 were expressed as peptides fused in frame to an
N-terminal 2xHA epitope tag. A vector designated pCX4pur-FH-TRIM56 was
constructed by swapping the cDNA fragment encoding TRIM56 from pcDNA5/FRT/TO
backbone to pCX4pur-Flag-HA vector to ensure expression of TRIM56 fused with Nterminal Flag-HA tandem tags (FH-TRIM56). The identities of all plasmids were
confirmed by DNA sequencing. pFlag-TRIF-mRHIM encoding a Flag-tagged,
constitutively active form of human TRIF (here referred to as Flag-TRIFSA) has been
described elsewhere (39). pCMV1-Flag-TLR3 was a gift from Ruslan Medizhitov (Yale
University).
__________________
1

Adapted with permission. Liu B, Li NL, Wang J, Shi PY, Wang T, Miller MA, Li K.
2014. Overlapping and distinct molecular determinants dictating the antiviral activities of
TRIM56 against flaviviruses and coronavirus. J Virol 88:13821-13835; Liu B, Li NL,
Shen Y, Bao X, Fabrizio T, Elbahesh H, Webby RJ, Li K. The C-terminal Tail of
TRIM56 Dictates Antiviral Restriction of Influenza A and B Viruses by Impeding Viral
RNA Synthesis. J Virol 2016. pii: JVI.03172-15.
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Table 2-1.

Mutagenesis primers for human (hT56) or mouse (mT56) TRIM56.

Mutations

Primer sequences (5’ Æ 3’)

hT56-S469A

Forward: ATATCCCGGGAGCCCAGCCCAG
Reverse: CGCCTTGAGCCTGCCTTTGAAC

hT56-S471A

Forward: GCTCGAGAGCCCAGCCCAGCCCT
Reverse: AATTGACTTGAGCCTGCCTTTGA

hT56-S475A

Forward: GCTCCAGCGCTGGGGCCGAATCT
Reverse: GGGCTCCCGGGAAATTGACTTGA

hT56-S710A

Forward: GCTCTCCTTGGAGACTTCCTG
Reverse: TCCCTTCGGGTCCAGGATCAC

hT56-S710D

Forward: GATCTCCTTGGAGACTTCCTG
Reverse: TCCCTTCGGGTCCAGGATCAC

hT56S469A+S471A+S475A

mT56-S689A

Forward:
GAGCCCGCTCCAGCCCTGGGGCCGAAT
Reverse:
TCGAGCAATAGCCTTGAGCCTGCCTTTGA
Forward: GCTCTTCTTGGTGACTTCCTAAC
Reverse: TCCCTTGGGATCCAGTATCAC
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The plasmid pcDNA6-YFVpro contained the full-length NS2B-NS3 coding sequence
of yellow fever virus (YFV)-17D in pcDNA6/V5-HisB backbone (40). Recombinant
plasmids encoding the TSV01 strain of dengue virus-2 (DENV2) replicon (pACYC-TSVRep-WT) and its replication-deficient, NS4B P104R mutant (pACYC-TSV-NS4BP104R) were gifts from Pei-Yong Shi (41). The full-length N coding sequence of HCoVOC43 was amplified from cDNA of virally infected BSC-1 cells and ligated into
pEF6/V5-His-TOPO (Invitrogen), to generate the pEF6-OC43-N-V5His construct in
which the N gene is fused in frame to C-terminal V5-His6 epitope tags. The identities of
all plasmids were confirmed by DNA sequencing.
Plasmids for luciferase (luc) reporter-based IAV RNA synthesis assay were gifts from
Richard Webby (St. Jude Children’s Research Hospital), which include polymerase IIdriven pHW plasmids expressing PB2, PB1, PA and NP of influenza A/PR/8/34 virus,
and a polymerase I-driven luc reporter plasmid (pHY-Luci), which expresses in the
negative sense the firefly luciferase flanked by noncoding sequences from the IAV matrix
(M) segment (42).
Cell Lines
Human embryo kidney (HEK) 293, 293-TLR3 cells (HEK293 cells constitutively
expressing human TLR3), HeLa, mosquito C6/36, African green monkey kidney Vero,
Vero-E6, BSC-1 and Madin-Darby canine kidney (MDCK) epithelial cell lines were
maintained in Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine
serum, 100 U/ml of penicillin and 100 μg/ml streptomycin. Madin-Darby bovine kidney
(MDBK) and its derivative cells were grown in medium containing horse serum in lieu of
FBS. Human hepatoma Huh7.5-TLR3 cells with TLR3 stable expression (Huh7.5-TLR3)
were described previously (43). HEK293-T3Y-FH-T56 cells constitutively expressing
FH-TRIM56 were generated by transducing HEK293-TLR3-YFP (293-T3Y, a gift from
Kate Fitzgerald, University of Massachusetts) cells with replication-incompetent
retroviruses carrying FH-T56 in pCX4pur backbone (pCX4pur-FH-TRIM56), followed
by stable selection with puromycin. MDBK cell pools stably expressing C-terminal Flagtagged, WT or various mutant human TRIM56 (MDBK-T56 WT/Mut), or an empty
vector (MDBK-Bsr), have been described elsewhere (34). Human osteosarcoma U2OS
cell pools stably expressing TRIM56-Flag (referred to as U2OS-T56) and control U2OSBsr cells expressing an empty retroviral vector (pCX4-Bsr) were developed by retroviral
gene transfer, followed by stable selection with blasticidin, as described (34).
HEK293 cells constitutively expressing WT or the E3 Ub ligase-deficient
CC21/24AA mutant (Cys21 and Cys24 in the RING domain substituted with alanines)
TRIM56 (designated as 293-T56 and 293-T56-CC21/24AA, respectively), were
generated by transducing HEK293 cells with replication-incompetent retroviruses
carrying C-terminal Flag-tagged WT and CC21/24AA mutant TRIM56 in pCX4bsr
backbone, respectively, followed by stable selection with blasticidin (35).
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HeLa-Flp-In T-REx-ACE2 (FitA2) cells with tetracycline (tet)-inducible expression
of HA-tagged, WT and various mutant versions of TRIM56, have been described and
designated as HeLa-FitA2-T56 WT/Mut (39). Herein we created the HEK293 cell lines
conditionally expressing WT or various mutant versions of TRIM56 (different deletion
mutants, or CTT135, CTT63 or S469A, S471A, S475A, S710A or
S469A+S471A+S475A) using the Flp-In T-REx (FIT) expression system (Invitrogen)
following the manufacturer’s recommended protocol. In brief, 293-FIT cells were cotransfected with pOG44 encoding the Flp recombinase and pcDNA5/FRT/TO-HATRIM56 or the indicated TRIM56 mutants in pcDNA5/FRT/TO-HA backbone at 9:1
ratio, followed by stable selection of cells in media containing 200 μg/ml of hygromycin.
The resultant cell lines were named 293-FIT-T56 or 293-FIT-T56-Mut, respectively. To
induce the HA-TRIM56 (or mutant HA-TRIM56) expression in 293-FIT- and HeLaFitA2-derived cells, cells were cultured in tet-containing medium for 48 h.
Viruses, Viral Infections, Replication Assays and Miscellaneous Reagents
YFV-17D (NR-115; BEI Resources) and DENV2 (Thailand 16681 strain) were
propagated in Vero-E6 and C6/36 cells, respectively. Viral stock of HCoV-OC43 (ATCC
VR-1558) was prepared in BSC-1 cells. EMCV (ATCC VR-1314, provided by Lawrence
Pfeffer) was propagated in Vero cells. Viral stocks of influenza A/PR/8/34 (H1N1) virus
(ATCC VR-1469) and B/Florida/4/06 (Yamagata-lineage) virus (provided by Richard
Webby) were propagated and viral titers determined in MDCK cells. A recombinant
vesicular stomatitis virus (VSV) expressing firefly luciferease, VSV-Luc, was a gift from
Sean Whelan (Harvard Medical School). VSV-Luc stocks were prepared in Vero cells
(44). Human metapneumovirus (hMPV) stocks were propagated and viral titers
determined in LLC-MK2 cells (45). Sendai virus (SeV, Cantell strain) was purchased
from Charles River Laboratories and used to infect cells at 100 HAU/ml for 12 h. Viral
infections of cells were conducted as described (34,40,46-48). Progeny infectious virus
titers in cell-free culture supernatants were determined by endpoint dilution-based 50%
tissue culture infective dose (TCID50) assays in 96-well plates (43,49). Specifically,
titration of YFV and EMCV was performed on Vero-E6 cells while HCoV-OC43
titration on BSC-1 cells. Cytopathic effect (CPE) was recorded and used for calculation
of virus yield on 7 days post-infection (dpi) for YFV-17D and HCoV-OC43, and on 3 dpi
for EMCV, respectively. Because infection by DENV2 does not cause obvious CPE,
titration of virus yield was performed on Vero cells on 3 dpi using immunofluorescence
staining to score prM-positive cell wells. TCID50 assays was also performed to determine
progeny infectious virus titers of IAV/IBV in cell-free culture supernatants, on
monolayers of MDCK cells (34,46,48). Cytopathic effect was recorded and used for
calculation of infectivity at 24 hours postinfection (hpi) for IAV and 48 hpi for IBV,
respectively. All resultant viral titers were expressed as TCID50/ml.
Poly-I:C (a dsRNA surrogate) was obtained from Sigma. To stimulate cells, poly-I:C
(pIC) was added into culture medium at a final concentration of 20 μg/ml. TNF-α and IL1β were used at a final concentration of 10 ng/ml for cell stimulation.
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Transient Replicon Assay
The Renilla luciferase-encoding, WT and NS4B P104R mutant DENV2 replicons
were synthesized from Cla I-linearized plasmid templates by in vitro transcription as
described elsewhere (41). 293-FIT-T56 cells cultured in the absence or presence of tet
(3×105 cells) were transfected with 1 μg of WT or the NS4B mutant replicon RNA using
DMRIE-C (Invitrogen) as per instructions from the manufacturer. At 4 h post
transfection, cells were split and seeded in 24-well plates. At various time points post
transfection, cells were lysed in 200 μl 1× lysis buffer (Promega). Thirty microliters of
cell lysates were subject to Renilla luciferase assay (Promega).
RNA Interference
For stable knockdown of human TRIM56, we used a short hairpin RNA (shRNA)
targeting the coding region of human TRIM56 gene inserted in the pLKO.1-puro vector
that was purchased from Openbiosystems (referred to as shT56-094). The target sequence
is: 5’-GCAGCAGAATAGTGTGGTAAT-3’ (34-36). In addition, for stable knockdown
of endogenous human TRIM56 without impact on the expression of exogenously
introduced TRIM56, I used another shRNA which specifically targets the 3’ untranslated
region (UTR) region of TRIM56 gene and was inserted in the pLKO.1-puro vector
(referred to as shT56 #093). The target sequence is: 5’CGTCTTCTAGTGTGTGAGAAT-3’. As a negative control, a non-targeting scrambled
shRNA, also cloned in pLKO.1-puro (Addgene #1864), was used (34-36). The shRNAs
were packaged into replication-incompetent lentiviral particles in 293FT cells, and
subsequently used to infect indicated cell lines. Following selection in medium
containing 2-5 μg/ml of puromycin for 2-3 weeks, surviving cell colonies were pooled
for further analysis. For transient knockdown of endogenous TRIM56 in 293-FIT-T56WT/Mut cells without down-regulating the expression of exogenously introduced HATRIM56-WT/Mut, I employed an siRNA (Fisher Scientific) that specifically targets the
3’ UTR of human TRIM56 transcript (35). This siRNA had a target sequence of 5’GCCGCTGCTATATAGTTTA-3’, and was transfected into cells at a final concentration
of 100 nM by Lipofectamine 2000 (Invitrogen) as per the manufacturer’s instructions. To
silence the expression of STING, I transfected cells with a mixture of two shRNAs
targeting the coding region of human STING transcript (TRCN0000160281 and
TRCN0000163296, Openbiosystems). To knockdown TRIF or RIG-I, I used synthetic
siRNAs that have previously been described (11,50). The target sequences were: TRIF1077, GAAGATACCACCTCTCCAA; RIG-I, GGAAGAGGTGCAGTATATT.
MDBK cells with stable knockdown of endogenous bovine TRIM56 (boT56) have
been described elsewhere (34). To knock down exogenously expressed human TRIM56
in MDBK-T56 cells, shT56-#094 or a non-targeting scrambled shRNA (as a negative
control) were packaged into replication-incompetent lentiviral particles in HEK293FT
cells, and subsequently used to transduce MDBK-T56 cells, respectively (36). Following
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selection in medium containing 2-5 μg/ml of puromycin for 2-3 weeks, survived cell
colonies were pooled for further analysis.
RNA Analyses
Extraction of total cellular RNA by TRIzol, cDNA synthesis by reverse transcription
and quantitative PCR (qPCR) were implemented as described elsewhere (34,51). The
following primers were used: ISG56 and 28S (39); IFN-β (51); IL29, 5’GAAGAGTCACTCAAGCTGAAAAACTG-3’ (forward) and 5’GAGAAGCCTCAGGTCCCAATT-3’ (reverse); TRIM56 coding region (34); TRIM56
3’UTR, 5’-CCGAGGACATTTTCCTGAAG-3’ (forward) and 5’AGTTAAGGTCACGCCACCAC-3’ (reverse); TRIF, 5’GTGGAGGAAGGAACAGGACA-3’ (forward) and 5’TGAGTAGGCTGCGTTCAGTG-3’ (reverse); RIG-I, 5’GGACGTGGCAAAACAAATCAG-3’ (forward) and 5’ATTGTGATCTCCACTGGCTTTGA-3’ (reverse); STING, 5’
TCAAGGATCGGGTTTACAGC-3’ (forward) and 5’TGGCAAACAAAGTCTGCAAG-3’ (reverse); YFV NS2B region, 5’TGAACAAGGGGAGTTCAAGC-3’ (forward) and 5’AGGACCAGCAGAAGAGCAAA-3’ (reverse); HCoV-OC43 N gene, 5’CGATGAGGCTATTCCGACTAGGT-3’ (forward) and 5’CCTTCCTGAGCCTTCAATATAGTAACC-3’(reverse) (52). The relative abundance of
each target was normalized to that of 28S rRNA. Copy numbers of YFV and HCoVOC43 RNAs were calculated based on standard curves generated using serially diluted
pcDNA6-YFVpro and pEF6-OC43-N-V5His DNA, respectively.
To analyze the abundance of three different influenza viral RNA species, RT was
performed using strand- and sense-specific oligonucleotides for vRNA, anti-genomic
complementary RNA (cRNA) and mRNA as previously described (26). A 28S-specific
primer (5’ CTTAACGGTTTCACGCCCTC 3’) was also included in the RT reaction
mixture for vRNA or cRNA analysis. Subsequently the following primers were used for
qPCR: M segment of influenza A/PR/8/34 virus, 5’ GACCRATCCTGTCACCTCTGAC
3’ (forward) and 5’ AGGGCATTYTGGACAAAKCGTCTA 3’ (reverse); and
hemaglutinin (HA) segment of influenza A/PR/8/34 virus, 5’
GGCCCAACCACAACACAAAC 3’ (forward) and 5’ AGCCCTCCTTCTCCGTCAGC
3’ (reverse). The qPCR primers for measuring mRNA abundance of SeV P gene are, 5’CTCTGGGAGAACAAGCAAGC-3’ (forward) and 5’TCGCCCAGATCCTGAGATAC-3’ (reverse). The relative abundance of each target was
normalized to that of 28S rRNA.
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Luciferase Reporter-based Minigenome Replication Assay of IAV RNA Synthesis
Luciferase reporter-based minigenome replication assay for monitoring IAV
transcription and replication was performed as previously described (42,53,54). In brief,
HEK293-FIT-T56-WT or -Mut cells cultured in the presence or absence of tet (to induce
or repress HA-T56 WT/Mut expression, respectively) were co-transfected using
Lipofectamine 3000 (Invitrogen) with polymerase II-driven pHW plasmids expressing
RNP complex genes (PB2, PB1, PA and NP) of influenza A/PR/8/34 virus, and a
polymerase I-driven luciferase reporter plasmid pHY-Luci (42). Also co-transfected was
a CMV promoter-driven plasmid expressing the Renilla luciferase (pRL-CMV,
Promega), which served as an internal control for normalization of transfection
efficiency. At the indicated time points post transfection, cells were lysed and processed
for dual-luciferase assay.
Immunoblotting, Immunofluorescence Staining, and Confocal Microscopy
Cell lysates were prepared in RIPA buffer and subjected to SDS-PAGE and
immunoblot analysis as previously described (34,50). Immunofluorescence staining and
confocal microscopy were performed as previously described (34,50). The following
monoclonal (mAb) and polyclonal antibodies (pAb) were utilized: rabbit anti-YFV NS3
pAb (a gift from Charles Rice), which we found to cross-react with DENV2 NS3; mouse
anti-DENV mAb D1-11(3) (Genetex); mouse anti-DENV prM (clone 2H2) hybridoma
culture supernatant; goat anti-DENV (BEI Resources), which we found to recognize
predominantly prM; anti-EMCV 3D pol mAb (a gift from Ann Palmenberg); mouse antiHCoV-OC43 N mAb (Millipore); mouse anti-influenza A/WSN/33 (H1N1) NP 5/1 mAb
(confirmed to react with the NP of A/PR/8/34 virus) and goat anti matrix (M) protein
antiserum (gifts from Richard Webby); goat anti-influenza B/Hong Kong/8/73 HA pAb
(BEI Resources NR-3165), which also reacts with the HA of B/Florida/4/06 virus; rabbit
anti-SeV pAb (a gift from Ilkka Julkumen); rabbit anti-hMPV pAb (45); rabbit antiTRIM56 pAb; rabbit anti-TRIF pAb; mouse anti-HA tag mAb (Invivogen), which I have
confirmed not to react with the HA of either A/PR/8/34 or B/Florida/4/06 virus; mouse
anti-HA tag mAb (clone 12CA5, Roche); mouse anti-V5 tag mAb (Invivogen); mouse
anti-Flag M2 mAb (Sigma); mouse anti-actin mAb (Sigma); rabbit anti-β tubulin pAb
(Santa Cruz); peroxidase-conjugated secondary goat anti-rabbit, goat anti-mouse and
rabbit anti-goat pAbs; FITC-conjugated secondary goat anti-mouse pAb (Southern
Biotech); and Alexa Fluor 594-conjugated secondary donkey anti-mouse and chicken
anti-goat pAbs (Invitrogen). Densitometry quantification of protein bands of interest was
performed using the Image J software (NIH).

13

Reporter Gene Assay
IFN-β, IL-29 and PRDII promoter activities in transfected cells after different
treatments were measured using a luc reporter assay as described (39,50).
Statistical Analysis
Statistical differences were analyzed using students’ t-test with the SPSS 11.5
software where appropriate. All P values were two-tailed and P < 0.05 was regarded to
be statistically significant. Error bars represent standard deviations.
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CHAPTER 3. OVERLAPPING AND DISTINCT MOLECULAR
DETERMINANTS DICTATING THE ANTIVIRAL ACTIVITIES OF TRIM56
AGAINST FLAVIVIRUSES AND CORONAVIRUS1
Introduction
The innate immune system represents a primary and fundamental component of host
defense in the immediate-early phase of microbial infections. It is equipped with multilayered mechanisms. As sentinels to alert cells to the presence of invading viral
pathogens, pattern recognition receptors (PRRs) such as the toll-like receptors (TLRs)
and retinoic-inducible gene-I (RIG-I)-like receptors sense viral nucleic acids, a major
class of viral pathogen-associated molecular pattern, activating intracellular signaling
pathways that culminate in production of interferons (IFNs). These antiviral cytokines act
in a paracrine/autocrine fashion to induce the expression of hundreds of interferonstimulated genes (ISGs) that collectively establish an antiviral state, reining in viral
replication and spread (1-4). In addition to the IFN system, mammalian hosts encode a
number of intracellular restriction factors that have direct antiviral roles (5). Although
most of these factors are constitutively expressed at variable levels, many are, not
surprisingly, also shown to be IFN-inducible. Of these, members of the tripartite motifcontaining (TRIM) protein family are increasingly recognized as active players in
antiviral innate immunity (28-30).
The TRIM protein family comprises more than 70 members whose functions span a
broad array of physiological processes, including cell proliferation, differentiation, and
development, etc (28,31). Structurally, TRIM family members have highly conserved
arrangement of N-terminal tripartite motifs, i.e., RING, one or two B-boxes, and coiledcoil domains, and variable C-terminal region that has or has not up to four known
functional domains (for example, the PRY-SPRY motifs). In general, RING domains
confer TRIM proteins with E3 ubiquitin (Ub) ligase activity and the ability to recognize
E2 conjugating enzyme. B-box domains are considered as zinc-binding motifs important
for protein-protein interactions while coiled-coil domains facilitate self-association,
turning oligomerized TRIM family proteins into a scaffold for assembling multi-protein
complexes. In contrast, the C-terminal half of the TRIM family proteins have been
proposed to be involved in protein-protein interactions, for example, presenting the
substrate to an E2 conjugating enzyme. Based on the variability in C-terminal domain
composition, TRIMs can be classified into up to 11 subfamilies (C-I to C-XI), with nine
TRIM family members that lack a known C-terminal domain setting up subfamily C-V
(30,31).
___________________________
1

Adapted with permission. Liu B, Li NL, Wang J, Shi PY, Wang T, Miller MA, Li K.
2014. Overlapping and distinct molecular determinants dictating the antiviral activities of
TRIM56 against flaviviruses and coronavirus. J Virol 88:13821-13835.
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As exemplified by TRIM5D, the first and most characterized role in antiviral
immunity of TRIMs is their ability to act as retroviral restriction host factors (28,29,32).
In recent years, however, a small number of TRIMs have been appreciated for novel roles
in modulating antiviral innate immune signaling and in possessing direct antiviral
activities against viruses of other families (29-31). Of a handful of TRIMs falling into the
latter group, TRIM79α, a rodent-specific TRIM, restricts tick-borne encephalitis virus
(TBEV), a classical flavivirus, by targeting the nonstructural (NS)-5 protein for
lysosome-dependent degradation (55). TRIM56, a C-V subfamily member, is a virus- and
IFN-inducible factor possessing antiviral activity against bovine viral diarrhea virus
(BVDV) (34), a ruminant pestivirus classified within the family Flaviviridae shared by
TBEV. Although the precise mechanism of action remains elusive, the antiviral effect is
abolished by mutations that abrogate the E3 Ub ligase activity or by deletions within the
last ~130 amino acids (aa) of the C-terminus, suggesting the importance of the RING
domain-residing E3 ligase activity and C-terminal integrity in TRIM56’s anti-BVDV
actions. However, it is unknown whether the B-box or coiled-coil domains or other parts
of the C-terminal region also play a part in the antiviral barrier function of TRIM56. Also
left unanswered is the question of the specificity and spectrum of TRIM56’s antiviral
actions. Of particular interest, whether TRIM56 impacts medically important RNA
viruses has not been determined.
This study is the first to demonstrate that human TRIM56 possesses antiviral activity
against yellow fever virus (YFV) and dengue virus (DENV), two classical flaviviruses
that are threatening the well-beings of approximately half of the world’s population (56).
Additionally, I report that TRIM56 restricts a human coronavirus, HCoV-OC43, which is
responsible for a significant share of common cold cases. In contrast, I find that TRIM56
does not impact propagation of encephalomyocarditis virus (EMCV), a picornavirus,
suggesting TRIM56 does not act on positive-strand RNA viruses indiscriminately. By
extensive domain mapping, I discovered that distinct molecular determinants underpin
the observed antiviral effects against different viral families. Consistent with this, I found
that while TRIM56 inhibits flavivirus RNA replication, it acts at the stage of coronavirus
packaging/release. These data delineate the antiviral spectrum of TRIM56 against
positive-strand RNA viruses and shed novel light on the molecular basis of the versatility
and specificity, and the mechanisms of action of this host restriction factor against
medically-important RNA viruses.
Results
Ectopic Expression of TRIM56 Inhibits Propagation of YFV, DENV2 and HCoVOC43, but Not That of EMCV
We have previously reported that both human and bovine TRIM56 restrict the
replication of BVDV, a ruminant pestivirus in the family Flaviviridae, but have no
demonstrable effect on vesicular stomatitis virus (VSV), a rhabdovirus (34). To
understand the specificity and spectrum of the antiviral activity of TRIM56 against
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positive-strand RNA viruses, I determined the impact of human TRIM56 overexpression
on multiplication of four RNA viruses of three distinct viral families. These included two
medically-important flaviviruses, YFV and DENV2; a human coronavirus, HCoV-OC43;
and a picornavirus, EMCV.
To gauge the effect of TRIM56 without the confounding factor of clonal variation, I
established HEK293 cells with conditional expression of N-terminal HA-tagged TRIM56
using the FIT expression system. This strategy was chosen since it enables the
development of isogenic, stable cell lines harboring tet-inducible expression of a protein
of interest from a specific genomic location. The resultant cell line, designated as 293FIT-T56, exhibited no detectable HA-TRIM56 protein when cultured in the absence of
tet (-tet) but demonstrated robust HA-TRIM56 expression upon tet addition to culture
medium (+tet) (Figure 3-1A, left panel, compare lane 1 vs 2). When infected with YFV17D at an MOI of 0.1, cells without HA-TRIM56 expression (-tet) harbored high levels
of viral NS3 antigen at 24 hours post-infection (hpi) (lane 3). In contrast, in cells induced
for HA-TRIM56 expression (+tet) NS3 expression was abrogated (lane 4). In agreement
with this, there was an 8-fold reduction (P < 0.05) in progeny virus titers in supernatants
of 293-FIT-T56 cells cultured in the presence of tet as compared with those in the
absence of tet (Figure 3-1A, right panel). Similar results were obtained in HeLa cells
with tet-inducible expression of HA-TRIM56, i.e., HeLa-FitA2-T56 (Figure 3-1B),
confirming that the finding is not a cell type-specific phenomenon. We also observed that
stable, constitutive expression of C-terminal Flag-tagged TRIM56 (TRIM56-Flag) in
HEK293 cells via retroviral gene transfer (i.e., 293-T56 cells), blunted YFV-17D NS3
protein expression and progeny virus production over a 3-day observation period as
compared to control HEK293 cells (data not shown). Thus, the anti-YFV activity was
also reproduced when ectopic expression of TRIM56 was achieved using a different
expression system.
I next examined how TRIM56 overexpression affected propagation of DENV2, a
flavivirus closely related to YFV. As in the case of YFV-17D, replication of the 16681
strain of DENV2 was crippled in 293-FIT-T56 cells upon turning on HA-TRIM56
expression, as revealed by diminished expression of viral E protein (Figure 3-1C, left
panel, lane 3 vs 4) and an approximately 1-log decrease (P < 0.05) in infectious virus
production (right panel). Moreover, substantial reduction in prM protein abundance was
observed in HeLa-FitA2-T56 cells infected with DENV2 when HA-TRIM56 expression
was induced by addition of tet (Figure 3-1D, compare lanes 4 vs 3), corroborating
TRIM56-mediated inhibition of DENV2 infection in another cell line.
Since TRIM56 is most abundantly expressed in the lungs (34), I reasoned that
TRIM56 might contribute to cellular defense against respiratory viruses. I thus
investigated whether manipulation of TRIM56 abundance alters cellular permissiveness
for HCoV-OC43, a human coronavirus that typically causes common cold. Indeed, an
antiviral effect of TRIM56 was observed in 293-FIT-T56 cells infected with HCoVOC43, with cells induced for HA-TRIM56 expression exhibiting substantially lower viral
N protein abundance and producing 1-log (P < 0.05) fewer infectious viruses in culture
medium than cells not induced (Figure 3-1E).
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Figure 3-1. Ectopic expression of TRIM56 inhibits multiplication of YFV, DENV2
and HCoV-OC43, but not that of EMCV.
(A) Left: Immunoblot analysis of the expression of N-terminal HA-tagged TRIM56
(using anti-HA antibody) and YFV NS3 in 293-FIT-T56 with or without tetracycline (tet)
and mock infected or infected with YFV-17D for 24 h (MOI = 0.1). Right: Progeny virus
production was determined by TCID50 assay in culture supernatants of 293-FIT-T56 cells
with or without tet treatment at 24 hours post-infection (hpi) with YFV-17D (MOI = 0.1).
Asterisk (*) denotes that statistical differences exist between -tet and +tet cells with a P
value of < 0.05. (B) HeLa-FitA2-T56 cells inhibited NS3 protein expression at 72 hpi of
YFV-17D (MOI = 0.5). (C, E and F) Left panels: Immunoblot analysis of of HATRIM56 and viral protein expression in mock- or viruses-infected 293-FIT-T56 cells
with or without tet treatment. Right panels: progeny viral titers for the infected cells in
the absence or presence of tet treatment, under similar experimental settings of (A) except
that the cells were infected with DENV2-16681 strain (MOI = 0.1) for 24 h for
immunoblot analysis and 72 h for TCID50 assay in (C), with HCoV-OC43 (MOI = 0.1)
for 24 h in (E), or with EMCV (MOI = 0.01) for 18 h in (F), respectively. The viral
protein antibodies used for immunoblotting included anti-DENV2 envelope (E) in (C),
anti-HCoV-OC43 nucleocapsid (N) protein in (E), and anti-EMCV 3D polymerase (pol)
in (F). (D) Tet-inducible expression of HA-TRIM56 in HeLa-FitA2-T56 cells inhibited
prM protein expression at 36 hpi of DENV2 (MOI = 0.1).
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Given that all positive-strand RNA viruses replicate on cytoplasmic membranes (57)
and that TRIM56 exhibits a cytoplasmic distribution, I wondered whether TRIM56 also
inhibits other positive-strand RNA viruses. I thus examined the effect of conditional
expression of HA-TRIM56 on propagation of EMCV, a prototype member of the family
Picornaviridae. Western blotting revealed 293-FIT-T56 cells with or without HATRIM56 induction supported comparable production of 3D polymerase protein, the
replicase core of EMCV, following infection with the virus (MOI = 0.01) (Figure 3-1F,
left panel). In line with this, there was no appreciable difference in progeny virus yields
in culture supernatants between tet-treated and tet-untreated cells (Figure 3-1F, right
panel). These data reveal that although ectopic expression of TRIM56 impedes the
multiplication of flaviviruses (YFV and DENV2) and HCoV-OC43, it does not target
positive-strand RNA viruses indiscriminately, since TRIM56 has no demonstrable
antiviral activity against EMCV.
In aggregate, the aforementioned experiments delineate the antiviral spectrum of
TRIM56 against positive-strand RNA viruses and reveal that when ectopically expressed,
this TRIM protein acts to curb infections by flaviviruses (YFV and DENV2) and HCoVOC43.
TRIM56 Expressed at Physiologic Levels Restricts Infections by YFV, DENV2 and
HCoV-OC43
Next, I determined whether TRIM56 expressed at physiologic levels poses a barrier
to infection with the three RNA viruses identified above. To achieve this goal, I stably
knocked down endogenous TRIM56 and measured the impact on viral protein expression
and progeny virus production. Compared with that in HeLa cells bearing a non-targeting,
scrambled control (Ctrl) shRNA, TRIM56 protein abundance in pools of HeLa cells
stably transduced with a TRIM56 shRNA (HeLa-shT56-094 cells) was reduced by ~80%
(Figure 3-2A, left panel). When infected with YFV-17D, HeLa-shT56-094 cells had
markedly elevated NS3 protein levels and a >1-log increase (P < 0.05) in progeny virus
yields as compared with HeLa-Ctrl cells (Figure 3-2A). Moreover, the enhanced YFV
replication in TRIM56 knockdown cells was confirmed by immunostaining of YFV NS3
expression (data not shown). TRIM56 depletion also rendered cells more permissive to
DENV2. As shown in Figure 3-2B, following DENV2 infection, we observed elevated
DENV NS3 expression (immunoblotting data in left panel), increased progeny virus
yields (middle panel) and higher percentage of cells with discernable prM expression
(right panel) in TRIM56 knockdown cells compared with the control cells. Thus, the
effects of TRIM56 depletion on DENV mirrored with those seen in YFV-17D-infected
cells. The same can be said concerning the impact of TRIM56 silencing on HCoV-OC43
infection; we found that HeLa-shT56-094 cells supported higher levels of viral N protein
expression and produced 6-fold more (P < 0.01) progeny viruses than HeLa-Ctrl cells
(Figure 3-2C). Collectively, the TRIM56 knockdown experiments corroborate the
physiologic relevance of the finding that TRIM56 is an intrinsic host restriction factor of
YFV, DENV2 and HCoV-OC43.
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Figure 3-2. The endogenous TRIM56 protein restricts propagation of YFV,
DENV2 and HCoV-OC43.
(A) Left panel: Immunoblot analysis of the expression of TRIM56 (using anti-TRIM56
antibody) and YFV NS3 (using anti-YFV NS3 antibody) in HeLa cells stably transduced
with either a non-targeting, scrambled control shRNA (Ctrl) or TRIM56 shRNA-094
(shT56) at 72 hpi with YFV-17D (MOI = 0.5). Actin served as a loading control to
demonstrate equal sample loading. Right panel: Culture supernatants of virus-infected
cells were harvested at 36 hpi and subjected to TCID50 assay for determination of
progeny virus production. (B) Left panel: Immunoblot analysis of TRIM56 and DENV2
NS3 (using anti-YFV NS3) expression in HeLa-Ctrl and HeLa-shT56-094 cells at 60 hpi
with DENV2-16681 (MOI = 1.5). Middle panel: Progeny virus titers in culture
supernatants of the DENV2-infected cells (MOI = 0.5, 60 hpi). Note that HeLa-Ctrl cells
produced 12-fold fewer progeny viruses than HeLa-shT56-094 cells. Right panel:
Immunostaining of DENV2 prM expression (using DENV 2H2 hybridoma supernatant)
in HeLa-Ctrl and HeLa-shT56-094 cells at 60 hpi with DENV2-16681 strain (MOI =
0.5). The mean percentage of cells with discernable prM expression was quantified from
three independent images and shown at the lower left corner of each prM panel. (C) Left
panel: Immunoblot analysis of TRIM56 and N protein (N) (using anti-HcoV OC43 N)
expression in HeLa-Ctrl and HeLa-shT56-094 cells at 48 hpi with HCoV-OC43 (MOI =
0.01). Right panel: Progeny virus titers in culture supernatants of the virus-infected cells.
“*”and “**” indicate that statistical differences exist between Ctrl and shT56 cells with a
P value of < 0.05 and < 0.01, respectively.
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The Antiviral Effects of TRIM56 Are Not Attributed to General Augmentation of
IFN Response or to Regulation of Cell Growth
TRIM56 possesses the ability to promote type I IFN response induced via the TLR3
signaling pathway (39). In light of this, I studied whether heightened induction of the IFN
antiviral response is responsible for the retarded viral propagation in TRIM56-expressing
cells. To this end, I examined induction of ISG15 and/or ISG56, well-characterized
sensitive markers of the IFN response, in cells with or without TRIM56 expression and
infected with YFV and HCoV-OC43, respectively. As shown in Figure 3-3A, there was
no detectable ISG15 protein in control HEK293 or 293-T56 cells infected with YFV17D, although robust induction of ISG15 was observed in these cells following Sendai
virus infection. Thus, regardless of the status of TRIM56 expression, there is no
discernable IFN response when infected with YFV. Likewise, expression of ISG15 or
ISG56 was undetectable in 293-FIT-T56 with or without HA-TRIM56 induction, and
prior to and after HCoV-OC43 infection (Figure 3-3B), despite that there was a
substantial decline in N protein abundance in these cells upon turning on HA-TRIM56
expression (lanes 4 vs 3, Figure 3-3B). Consistent with these data, there was no
significant up-regulation of transcription for ISG56, IFN-β, or IL-29, in 293-FIT-T56
cells with (+tet) or without (-tet) HA-TRIM56 induction when infected with YFV,
DENV2 or HCoV-OC43 (data not shown). I conclude from these data that general
augmentation of the IFN antiviral response is not responsible for the antiviral effects of
TRIM56 against flaviviruses and HCoV-OC43.
I also considered the possibility that TRIM56 may impact cell growth, producing a
condition unfavorable for viral propagation. However, I did not find any difference in cell
proliferation between 293-FIT-T56 cells induced and repressed for HA-TRIM56
expression over a seven-day observation period (Figure 3-3C), nor did I observe obvious
cell death or apoptosis before and following tet-induction of HA-TRIM56 (data not
shown).
TRIM56’s Antiviral Actions Do Not Depend upon TLR3/TRIF, RIG-I or STING
TRIM56 has been reported to form a complex with TRIF and STING, thereby
potentiating TLR3 and STING-dependent antiviral signaling pathways, respectively
(39,58). Although I did not find heightened IFN or ISG induction to be responsible for
TRIM56’s antiviral activities, the possibility could not be ruled out that IFN-independent
mechanisms through the TLR3/TRIF-, RIG-I-, or STING-axis may contribute. To clarify
this, I determined whether knockdown of TRIF, RIG-I or STING alters the antiviral
activities of TRIM56 against YFV and HCoV-OC43. HEK293-derived cells generally
have very low expression of TLR3, and I found this to be the case with the 293-FIT cells
(data not shown). In line with this, there was little induction of ISG56 transcript in
extracellular poly-I:C-stimulated cells without HA-TRIM56 induction (Figure 3-4A, tet). Turning on HA-TRIM56 expression (+tet) strongly augmented induction of ISG56
by poly-I:C, but this response was curtailed upon TRIF silencing (Figure 3-4A). This is
consistent with our previous report that TRIM56 positively regulates TLR3
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Figure 3-3. The antiviral effects of TRIM56 do not result from up-regulation of
IFN response or from modulation of cell growth.
(A) Immunoblot analysis of ISG15 protein abundance in 293 cells or cells stably
overexpressing TRIM56-Flag (293-T56) at 24 hpi with YFV-17D (MOI = 0.1) or at 12
hpi with Sendai virus (SeV) as a positive control for induction of the IFN response. (B)
Immunoblot analysis of HA-TRIM56, HCoV-OC43 N protein, ISG15, and ISG56
expression in 293-FIT-T56 cells that were mock infected or infected with HCoV-OC43
(MOI = 0.1) for 24 h in the absence (odd numbered lanes) or presence (even numbered
lanes) of tet treatment. Asterisk indicates a nonspecific band detected by the anti-ISG56
antibody. (C) Growth curves of 293-FIT-T56 cells cultured with or without tet was
assessed by cell number counts over a 7-day observation period.
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Figure 3-4. TRIM56’s antiviral actions are independent of TRIF, RIG-I and
STING.
HEK293-FIT-T56 cells cultured without (-tet) or with tet (+tet) were transfected with a
negative control siRNA (si-ctrl) or siRNA targeting TRIF or RIG-I, or shRNA targeting
STING (shSTING) or its control vector (Ctrl). At 48 h post transfection, the cells were
mock-treated, infected with YFV-17D or HCoV-OC43 for 24 h (MOI = 0.1), or treated
with poly-I:C (pIC) or Sendai virus (SeV) for 10 h. qPCR was performed with total
cellular RNA to measure abundance of TRIF and ISG56 mRNAs before or after pIC
treatment in (A), or that of RIG-I and ISG56 mRNAs before and following SeV infection
in (B). (C) Progeny virus production was determined in cell-free supernatants following
silencing TRIF or RIG-I and infection of YFV-17D (left) or HCoV-OC43 (right). (D)
Left panel shows qRT-PCR analysis of the abundance of STING transcript after
transfection of control vector or shSTING. Progeny virus production was determined in
cell-free supernatants following transfection of control vector or shSTING and infection
with YFV-17D (middle) or HCoV-OC43 (right). “*” and “**” denote that statistical
differences exist between -tet and +tet cells (C and D), or between ctrl and knockdown
cells (A and B) with a P value of < 0.05 and < 0.01, respectively.

23

signaling by interacting with TRIF (39). Also in agreement with our previous finding that
TRIM56 has no appreciable role in RIG-I signaling (39), tet-induction of HA-TRIM56
had no effect on upregulation of ISG56 mRNA by Sendai virus infection, which was
blunted by RIG-I siRNA (Figure 3-4B). Despite efficient knockdown of TRIF or RIG-I,
TRIM56’s antiviral activities against YFV and HCoV-OC43 remained unchanged
(Figure 3-4C). I also did not find knockdown of STING alters TRIM56’s suppressive
effects on YFV or HCoV-OC43 multiplication (Figure 3-4D).
Development of HEK293 Cells with Conditional Expression of Various TRIM56
Mutants for Mapping of the Antiviral Determinants
In order to dissect the mechanisms by which TRIM56 exerts its antiviral actions
against different RNA viruses, it was necessary to define the domains/activities critical
for TRIM56’s restriction of each virus. Thus, I established HEK293 cell lines with tetinducible expression of a series of HA-TRIM56 mutants using the strategy we adopted to
generate the 293-FIT-T56 cell line. These included the E3 Ub ligase-deficient
CC21/24AA mutant (referred to as CC21/24AA), mutants lacking the RING (referred to
as ΔRING), B-box (referred to as ΔB-box) or coiled-coil (referred to as ΔCoiled-coil)
domains, respectively, and mutants bearing deletions in the C-terminal portion – Δ355433 (lacking aa 355-433), Δ621-695 (lacking aa 621-695), and Δ693-750 (lacking aa
693-750). As shown in Figure 3-5, there was negligible expression of WT and mutant
HA-TRIM56 when these cell lines were cultured in tet-free medium (odd-numbered lanes
except lane 17), while robust expression of HA-TRIM56 and its mutants (even-numbered
lanes) with comparable levels and expected molecular masses was induced upon tet
addition.
The E3 Ligase Activity and the Integrity of the C-terminus of TRIM56 Are Critical
for the Antiviral Activity against YFV and DENV2, while the B-box Is Dispensable
Having created HEK293 cell lines with tet-regulated expression of various TRIM56
mutants, I used them in conjunction with the WT TRIM56-inducible 293-FIT-T56 cells
to map the molecular determinants dictating TRIM56’s antiviral activities against the
three RNA viruses. First, I examined how YFV-17D replication differed among these cell
lines. As shown in Figure 3-6A, tet induction of the ΔB-box mutant blunted YFV NS3
protein abundance (compare lanes 12 vs 11) in infected cells, acting with similar potency
to that of WT TRIM56 (compare lanes 4 vs 3). In stark contrast, this inhibitory effect was
absent when comparing cells expressing ΔRING, Δ355-433, Δ621-695 and Δ693-750
mutants with cells not induced to express (for ΔRING mutant, compare lanes 24 vs 23;
for Δ355-433 mutant, compare lanes 20 vs 19; for Δ621-695 mutant, compare lanes 28 vs
27; and for Δ693-750 mutant, compare lanes 32 vs 31). These data imply that the RING
domain and the integrity of the C-terminal parts are critical for the antiviral function of
TRIM56 against YFV, while the B-box is dispensable. To determine the involvement of
the E3 ligase activity, which lies in the RING-domain, I subjected the CC21/24AA
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Figure 3-5. Characterization of HEK293 cells that conditionally express
individual TRIM56 mutants in a tet-inducible manner.
Upper panel: Schematic representation of TRIM56 protein domains and the individual
TRIM56 mutants investigated in this study. Lower panel: Immunoblot analysis of HATRIM56 and actin expression in 293-FIT-T56 and the indicated 293-FIT-T56 Mut cells
with or without tet treatment for 48 h.
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Figure 3-6. The E3 ligase activity and the integrity of the C-terminal parts of
TRIM56 are essential for the antiviral activity against YFV.
(A) Immunoblot analysis of HA-tagged wild-type and mutant TRIM56 and YFV NS3
protein expression in 293-FIT-T56 WT/Mut cells in the absence (odd numbered lanes) or
presence (even numbered lanes) of tet, and mock-infected or infected with YFV-17D for
24 h (MOI = 0.1). There were eight lines of 293-FIT-T56 WT/Mut cells examined in
total, data from which are shown in eight blocks of immunoblot collections. (B) Progeny
virus production in culture supernatants of 293-FIT-T56 WT/Mut cells cultured in the
absence or presence of tet at 24 hpi with YFV-17D (MOI = 0.1).
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mutant inducible cells to YFV-17D infection. Tet induction of CC21/24AA mutant had
no effect on YFV NS3 expression (compare lanes 8 vs 7), indicating that the E3 ligase
activity plays a critical role in conferring the anti-YFV activity. This notion was
additionally supported by data obtained from YFV-17D-infected 293-T56 and 293-T56CC21/24AA cells in which TRIM56-Flag or its CC21/24AA mutant version was
expressed in a constitutive fashion (data not shown).
Consistent with the immunoblot results, there was a 10-13-fold decrease in progeny
virus production in 293-FIT-T56 and 293-FIT-T56-ΔB-box cells in the induced state
compared with cells cultured in the absence of tet. However, the decline in progeny viral
yield upon tet induction was not seen in 293-FIT-T56-CC21/24AA, -ΔRING, -Δ355-433,
-Δ621-695 or -Δ693-750 mutant cells (Figure 3-6B). Notably, an intermediate antiviral
phenotype was observed upon inducible expression of ΔCoiled-coil. While this mutant
retained the ability to inhibit YFV-17D, it was less effective than WT TRIM56 or the
ΔB-box mutant, as determined by immunoblotting of NS3 (Figure 3-6A, compare lanes
16 vs 15) and measurement of progeny virus production (Figure 3-6B). Thus, the coiledcoil domain is, to some extent, involved in the restriction of YFV by TRIM56, although
the part this domain plays is not as crucial as those played by the E3 ligase activity and
the C-terminal portions of the protein.
Next, I analyzed the molecular determinants that control the TRIM56 restriction of
DENV2 using 293-FIT-T56 cells and our panel of mutant TRIM56 inducible cell lines.
The TRIM56 domain involvement profile uncovered (Figure 3-7) was almost identical to
that required for the anti-YFV action. Yet, there was one exception – the ΔCoiled-coil
mutant still effectively inhibited the accumulation of DENV2 prM protein (Figure 3-7A,
compare lanes 16 vs 15) and progeny virus production (Figure 3-7B), similar to those
seen with WT TRIM56 or ΔB-box (Figure 3-7A-B), suggesting that unlike the case of
YFV, the anti-DENV2 action is not strictly dependent on TRIM56’s coiled-coil domain.
The Functional TRIM56 Mutants Exert Their Antiviral Effects Independent of the
Endogenous, WT TRIM56 Protein
I recognize one caveat concerning the experiments probing the antiviral functions of
the TRIM56 mutants. One cannot exclude the possibility that some of the mutants
functioned by pairing with the endogenous WT TRIM56 protein, despite their expression
levels in ectopic expression settings were ~12 fold higher than the latter (Figure 3-8B).
However, this scenario is unlikely. The coiled-coil domain that is responsible for
facilitating dimerization or oligomerization of TRIMs is dispensable for the antiviral
activities of TRIM56 against DENV2 (Figure 3-7B) and HCoV-OC43 (Figure 3-9B, see
the next section), except in the case of YFV (Figure 3-6B) it contributed to a minor
extent. To confirm this notion, I conducted siRNA knockdown experiments to efficiently
silence the endogenous TRIM56 mRNA (Figure 3-8A) without affecting the
exogenously introduced mutant TRIM56 expression (Figure 3-8B), using an siRNA
specifically targeting the 3’UTR region of the human TRIM56 transcript. As shown in
Figure 3-8C, knockdown of endogenous WT TRIM56 by this siRNA did not reverse the
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Figure 3-7. The suppression of DENV2 multiplication by TRIM56 requires its E3
ligase activity and the integrity of the C-terminal portions.
(A) Immunoblot analysis of HA-TRIM56 (WT or mut) and DENV2 prM protein
abundance (using goat anti-DENV2 antibody) in 293-FIT-T56 WT or individual Mut
cells in the absence (odd numbered lanes) or presence (even numbered lanes) of tet, and
mock-infected or infected with DENV2-16681 strain (MOI = 1) for 60 h. (B) Progeny
virus production in culture supernatants of 293-FIT-T56 WT/Mut cells cultured in the
absence or presence of tet at 60 hpi with DENV2-16681 strain (MOI = 1). “*” and “***”
indicate that statistical differences exist between -tet and +tet cells with a P value of <
0.05 and < 0.001, respectively.
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Figure 3-8. Knockdown of endogenous TRIM56 via an siRNA targeting the 3’
UTR of human TRIM56 transcript does not affect the antiviral activities of the
ectopically expressed WT TRIM56 or functional TRIM56 mutants.
qRT-PCR was performed to measure the abundance of endogenous TRIM56 transcript
(panel A, using primers amplifying the 3’ UTR of TRIM56 mRNA), total TRIM56
transcript including the endogenous and exogenously overexpressed TRIM56 mRNAs
(panel B, using primers amplifying the coding region of TRIM56 mRNA), and
intracellular YFV RNA (panel C, using primers amplifying the NS2B region of YFV
RNA) in 293-FIT-T56 (WT), 293-FIT-T56-'Coiled-coil and 293-FIT-T56-'B-box cells
cultured with or without tet, and transfected with a negative control siRNA (Ctrl) or
siRNA targeting 3’ UTR of TRIM56 (siT56). Cell were either mock-infected or infected
with YFV-17D for 24 h (MOI = 1). Note that the TRIM56-3’UTR siRNA only knocked
down endogenous TRIM56 transcript but not the exogenously introduced (tet-inducible)
WT or mutant TRIM56 which expressed only the coding region of the gene. (panel B); 3)
the 'Coiled-coil mutant inhibited YFV RNA replication less efficiently than WT
TRIM56 or the 'B-box mutant; and 4) the TRIM56-3’UTR siRNA had no demonstrable
effects on the antiviral activity of any of the exogenously expressed TRIM56 forms. “*”
and “**” denote that statistical differences exist between -tet and +tet cells (panel C), or
between control and knockdown cells (panel A) with a P value of < 0.05 and < 0.01,
respectively. “◊” denotes a P value of 0.05-0.06.
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significant dip in intracellular YFV RNA levels in 293-FIT-T56-ΔB-box or 293-FITT56-ΔCoiled-coil cells imposed by tet-induction of mutant TRIM56, suggesting that the
antiviral effects of these mutants are not dependent upon the endogenous WT protein.
TRIM56’s Suppression of HCoV-OC43 Multiplication Depends on Its E3 Ligase
Activity, but Not the Integrity of the C-terminus or B-box or Coiled-coil Domains
To determine whether the findings with TRIM56 domain/activity requirements for its
restriction of flaviviruses can be extended to HCoV-OC43, I compared the HEK293 tetinducible cell lines expressing WT or various TRIM56 mutants for their ability to support
HCoV-OC43 infection. I monitored expression of the viral structural N protein in cell
lysates by western blotting (Figure 3-9A) and progeny viral titers in culture supernatants
via TCID50 assay (Figure 3-9B). When infected with HCoV-OC43 at an MOI of 0.1,
abundant expression of N protein was detected in all cell lines that were cultured in tetfree medium at 24 hpi. However, upon induction of WT TRIM56 or mutants lacking Bbox or the coiled-coil domain, or any of the C-terminal deletion mutants (Δ355-433,
Δ621-695 and Δ693-750) by tet, N protein abundance was compromised (Figure 3-9A).
In contrast, there was no reduction in the expression level of this viral protein when the
tet-treated cells started to express the CC21/24AA or ΔRING mutants, both of which are
defective for E3 ligase activity (Figure 3-9A, compare lanes 8 vs 7 and lanes 24 vs 23,
respectively). Analysis of progeny virus production confirmed that all TRIM56 mutants
but CC21/24AA and ΔRING retained the ability to curtail HCoV-OC43 propagation
(Figure 3-9B). Taken together, these observations demonstrate that the E3 ligase activity
alone, and not other domains/portions of TRIM56, mediates the anti-HCoV-OC43effect.
TRIM56 Inhibits YFV/DENV2 Propagation by Impairing Intracellular Viral RNA
Replication, whereas It Curbs HCoV-OC43 Spread by Targeting a Later Step in the
Viral Life Cycle
Because TRIM56’s antiviral effects against flaviviruses and HCoV-OC43 share a
dependence on the E3 ligase activity but differ in the requirement of the C-terminal
regions, I wondered to what extent their mechanisms of actions overlapped. Thus, I
determined the effects of TRIM56 overexpression on different stages of YFV-17D (the
prototype of flaviviruses) and HCoV-OC43 life cycles. Three cell lines were included in
the analysis: 293-FIT-T56-WT, 293-FIT-T56-CC21/24AA, and 293-FIT-T56-Δ621-695.
Cells were cultured in the absence or presence of tet to repress or induce TRIM56 (or
mutant TRIM56) expression, respectively, followed by infection with YFV-17D
(Figure 3-10A) or HCoV-OC43 (Figure 3-10B) at an MOI of 1. At 1, 12 and 24 hpi,
after extensive washes to remove extracellular virus and viral RNAs, cells were lysed for
total RNA extraction, followed by measurement of intracellular viral RNA levels by
qPCR. Parallel assays of viral titers in culture supernatants at 24 hpi confirmed that
induction of TRIM56 but not CC21/24AA or Δ621-695 mutants significantly decreased
progeny YFV-17D yield, and that expression of WT TRIM56 or Δ621-695 but not
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Figure 3-9. The inhibition of HCoV-OC43 propagation by TRIM56 is dependent
upon its E3 ligase activity, but not upon the integrity of the C-terminal portions, or
the B-box or coiled-coil domains.
(A) Immunoblot analysis of HA-TRIM56 (WT or mut) and HCoV-OC43 N protein (N)
abundance in 293-FIT-T56 WT or individual Mut cells in the absence (odd numbered
lanes) or presence (even numbered lanes) of tet, and mock-infected or infected with
HCoV-OC43 (MOI = 0.1) for 24 h. (B) Progeny virus production in culture supernatants
of 293-FIT-T56 WT/Mut cells in the absence or presence of tet at 24 hpi with HCoVOC43 (MOI = 0.1).
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Figure 3-10. TRIM56 blunts YFV and DENV2 infection by targeting intracellular
viral RNA replication, but inhibits HCoV-OC43 propagation by acting on a later
step in the viral life cycle.
(A) qRT-PCR analysis of intracellular YFV RNA abundance in 293-FIT-T56 (WT), CC21/24AA or -Δ621-695 cells cultured in the absence or presence of tet, and mockinfected or infected with YFV-17D (MOI = 1) for 1, 12 and 24 h, respectively. (B) qRTPCR analysis of intracellular HCoV-OC43 N RNA abundance in 293-FIT-T56 (WT), CC21/24AA or -Δ621-695 cells cultured in the absence or presence of tet, and mockinfected or infected with HCoV-OC43 (MOI = 1) for 1, 12 and 24 h, respectively. (C)
293-FIT-T56 cells induced (+tet) or repressed (-tet) for HA-TRIM56 expression were
transfected with WT or the replication-defective NS4B P104R mutant DENV2-TSV01
replicon RNA (designated as DEN-Rep-WT or -Mut). At indicated time points post
transfection, cells were lysed and assayed for Renilla luciferase activity as readout of
DENV RNA replication. “*” and “***” indicate that statistical differences exist between
-tet and +tet cells with a P value of < 0.05 and < 0.001, respectively.
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CC21/24AA led to a significant dip in HCoV-OC43 titers (data not shown). At 1 hpi,
intracellular viral RNA levels for YFV-17D or HCoV-OC43 were indistinguishable
between cells cultured without and with tet, regardless of the cell line examined (bearing
WT or mutant TRIM56), suggesting that TRIM56 does not impede virus-receptor
interaction or early cellular entry of either virus.
However, as infection progressed a different picture regarding the effects of TRIM56
emerged between the two viruses. In the case of YFV-17D (Figure 3-10A), intracellular
viral RNA abundance peaked at 24 hpi, with no significant further increase at 36 hpi
(data not shown), and was comparable among all three cell lines cultured in tet-free
medium (without WT or mutant HA-TRIM56 induction). However, the peak level of
viral RNA in tet-induced 293-FIT-T56 cells was 1 log lower than in uninduced cells,
proportional to the difference in progeny viral titers. This implies that TRIM56 blunts
YFV infection by targeting intracellular viral RNA replication. In contrast, 293-FIT-T56CC21/24AA and -Δ621-695 cells in induced state harbored more viral RNA than those
cultured in the absence of tet, a phenomenon more appreciable at 12 than 24 hpi. The
moderate increase in viral replication in these cells may reflect a dominant-negative
effect of these TRIM56 mutants on endogenous WT TRIM56. In contrast to what was
observed with YFV, in cells infected with HCoV-OC43 (Figure 3-10B), copy numbers
of intracellular viral N RNA reached plateau at 12 hpi, and there was no difference
among 293-FIT-T56-WT, -CC21/24AA or -Δ621-695 cells irrespective of tet treatment.
Collectively, the significant decline in progeny HCoV-OC43 titers in 293-FIT-T56-WT
and -Δ621-695 cells in induced state does not arise from impaired viral entry or RNA
replication but rather is attributed to effect(s) of the TRIM56 E3 ligase on a later step in
the viral life cycle, most likely virus packaging and/or egress.
To corroborate that TRIM56 curbs flaviviral RNA replication, I performed transient
viral RNA replication assay in 293-FIT-T56 cells using WT or a replication-defective
mutant (NS4B P104R) DENV2 replicon encoding Renilla luciferase. At 4 h post
transfection, there was no difference in luciferase activity in cells transfected with either
WT or mutant replicon, regardless of HA-TRIM56 expression status, suggesting little
impact of TRIM56 on DENV2 RNA translation (Figure 3-10C). However, different
replication kinetics of the WT replicon were observed between +tet and -tet cells at later
time points. Specifically, in cells repressed for HA-TRIM56 expression (-tet), the WT
DENV2 replicon started to replicate at 24 h post transfection and climbed progressively
in the next 2 days (48 and 72 h, Figure 3-10C). In stark contrast, in cells with induced
HA-TRIM56 (+tet), the WT replicon did not replicate in the first 48 h. Although this
replicon began to replicate at 72 h, its replication level, as gauged by luciferase activity,
was significantly lower than that in -tet cells. As a negative control, the replicationdeficient NS4B mutant replicon failed to synthesize viral RNAs (41) and displayed a
continuous decline in luciferase activity, regardless of HA-TRIM56 expression status
(i.e., -tet or +tet) (Figure 3-10C, dashed lines). These data confirm that TRIM56 acts on
the viral RNA replication step of DENV2 infection.
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Discussion
In this study, I have examined the roles of human TRIM56 in acting as an antiviral
host factor against diverse positive-strand RNA viruses. Our data demonstrate that
TRIM56 bears antiviral activities against two medically-important flaviviruses (YFV and
DENV2) and extend the antiviral spectrum of this TRIM to include a human coronavirus
(HCoV-OC43). Not only did I show that ectopic expression of TRIM56 put a check on
these viruses (Figure 3-1), but our data obtained from cells depleted for the endogenous
protein confirmed that physiologic levels of TRIM56 posed an antiviral barrier
(Figure 3-2). No less important, the effects were reproduced in multiple cell types and
regardless of the expression system utilized. Of note, preceded by demonstration of an
inhibitory effect of TRIM56 on a ruminant pathogen, BVDV (34), the novel findings in
the present study, for the first time, show that human TRIM56 functions as a versatile
antiviral restriction factor of human-pathogenic positive-strand RNA viruses. Moreover,
this study has delineated the contributions of TRIM56’s B-box and coiled-coil domains
as well as the entire C-terminal portion to its novel antiviral functions. The full picture of
the molecular determinants underlying the observed antiviral effects sheds light on the
mechanisms of action of TRIM56.
We previously demonstrated that TRIM56 restricts the replication of BVDV (34).
The close relatedness of DENV and YFV to BVDV is in line with their shared sensitivity
to TRIM56’s antiviral actions. However, a seemingly contradicting observation
previously made was that TRIM56 failed to inhibit hepatitis C virus (HCV) replication
when overexpressed in human hepatoma Huh7 cells (34), the current cell culture model
permitting efficient propagation of this virus. Exactly why TRIM56 was inefficient in
curbing HCV (which is classified in the Hepacivirus genus within the family
Flaviviridae) is unknown. However, it is important to point out that Huh7 cells have
severely impaired antiviral responses (50,59). Perhaps one or more cellular cofactors
required for TRIM56’s antiviral actions are missing in this particular cell line. Indirectly
supporting this possibility, our group has previously found that ISG20, an IFN-inducible
exonuclease, acted as a potent inhibitor of YFV replication in HEK293 cells but had no
demonstrable antiviral activity in Huh7.5 cells, a subline of Huh7 cells (49). Clearly,
examining the effect of TRIM56 on HCV in other cell hosts is warranted. Along this line,
our attempts to establish HCV RNA replicons in the tet-inducible 293-FIT-T56 cells,
however, have thus far turned up fruitless for unknown reasons, although HEK293 cells
had previously been reported to support some selectable HCV RNA replicons at very low
efficiencies (60).
The discovery of TRIM56’s antiviral activity against a human coronavirus
substantially broadens our understanding of the antiviral spectrum of this TRIM.
Classified within the family Coronaviridae, HCoV-OC43 belongs to the genus
Betacoronavirus that is shared by two other highly pathogenic coronaviruses, severe
acute respiratory syndrome coronavirus and the newly-emerged Middle East respiratory
syndrome coronavirus (61). Coronaviruses differ remarkably from Flaviviridae members
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(e.g., YFV and DENV) in their transmission route, replication strategy and pathogenesis.
The newly-uncovered broad antiviral spectrum of TRIM56 is consistent with its
ubiquitous distribution across human tissues (34). Our novel findings raise the possibility
that TRIM56 may also act to defend cells against other RNA viruses of significant public
health concern.
TRIM56 is among a handful of TRIMs that were recently shown to positively
regulate innate antiviral pathways leading to IFNs production. Specifically, TRIM56
promotes the TLR3-dependent signaling pathway that recognizes viral double-stranded
(ds) RNAs by forming a complex with TRIF, independent of its E3 ligase activity (39).
TRIM56 also interacts with and activates STING, enhancing the cytosolic dsDNAsensing pathway (39,58). However, data from the current study suggest a heightened IFN
antiviral response does not underpin the antiviral effects of TRIM56 against YFV,
DENV2 and HCoV-OC43 (Figure 3-3 and data not shown). Neither was it the case
concerning the antiviral action of TRIM56 against BVDV (34). Consistent with IFNindependent antiviral mechanisms, overexpression of TRIM56 failed to inhibit VSV (34)
and EMCV (Figure 3-1F), two viruses widely used for IFN bioactivity assays because of
their extreme sensitivity to very low amount of IFNs. Moreover, siRNA knockdown
experiments ruled out the involvement of TRIF-, RIG-I- or STING-dependent
mechanisms in exerting the antiviral actions of TRIM56 (Figure 3-4). Despite the strong
in vitro evidence summarized above suggesting direct antiviral effects of TRIM56, the
possibility cannot be fully excluded that TRIM56 may promote innate immune signaling
to these RNA viruses in primary cells and/or immune sentinel cells in vivo, contributing
to viral clearance systematically. Future studies in TRIM56-deficient mice will be needed
to elucidate the exact contributions of this TRIM to host antiviral defense. It should be
noted, as well, given the growing evidence suggesting participation of the STINGdependent pathway in detecting DNA viruses and intracellular bacteria (62,63), it will be
of interest in future studies to investigate whether TRIM56 is also involved in cellular
processes that fend off these classes of parasites.
Previous studies on other TRIMs have suggested that different TRIMs exert their
antiviral effects via distinct mechanisms, which are dictated by different functional
domains/portions. The N-terminal RING domain executes E3 ligase activity that
promotes ubiquitination of viral proteins or host factors critical for viral replication,
which are typically destined for proteasome-dependent degradation, as exemplified by
TRIM22 E3 ligase-dependent degradation of influenza A virus nucleoprotein (29,30,33).
The B-box, coiled-coil domain and C-terminal portion (or the special domains lying in
it), mediate protein-protein interactions (or protein-nucleic acid interactions which is also
possible) that can perturb viral life cycles. Examples of this category include B-boxdependent TRIM15 restriction of murine leukemia virus (MLV) and the TRIM5α Cterminal SPRY domain-mediated inhibition of human immunodeficiency virus (HIV)
uncoating (32,64). Remarkably, different domain involvements can be well orchestrated
to perform TRIM-mediated antiviral functions. For instance, a model of TRIM E3 Ub
ligase function has been proposed in which the RING domain bearing catalytically-active
E3 ligase determines recognition of E2 conjugating enzyme meanwhile the coiled-coil
domain and C-terminal part ensure successful presentation of substrates to the E2 enzyme
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(29,65). However, sometimes only one category of domain is involved in viral restriction.
For example, TRIM15-mediated suppression of MLV requires its B-box domain alone,
independent of the E3 ligase activity or the C-terminal SPRY domain (64). In the case of
TRIM56, the overlapping and distinct domain requirement profiles unveiled in the
current study may illuminate how TRIM56 renders cells resistant to three positive-strand
RNA viruses from two distinct families.
TRIM56-mediated antiviral activities against YFV, DENV2 and HCoV-OC43 share
the requirement for the RING domain (Figures 3-6, 3-7 and 3-9). However, they differ in
the requirement of other molecular determinants. Specifically, while the E3 ligase
activity was the only requirement for TRIM56-mediated anti-HCoV-OC43 action
(Figure 3-9), the restriction of flaviviruses (YFV and DENV2) additionally depended on
the integrity of the C-terminal region of TRIM56 (Figures 3-6 and 3-7). When it comes
to the coiled-coil domain, our data show that this motif is dispensable for restricting
DENV2 and HCoV-OC43 (Figures 3-7 and 3-9), but contributes, to some extent, to antiYFV activity (Figure 3-6). Why there is a difference in the involvement of this domain
for anti-YFV and anti-DENV2 actions is unknown and will require further study. Given
that the coiled-coil domain is indispensable for homo- and hetero-dimerization of TRIMs
(66), I postulate that TRIM56 may not absolutely rely on self-oligomerization or its
pairing with another TRIM to curb infections by the RNA viruses investigated herein
except YFV. Of note, I did not observe a dependence on the B-box domain for any of the
TRIM56-mediated antiviral activities (Figures 3-6, 3-7 and 3-9), suggesting little
contribution from B-box to the antiviral actions against flaviviruses and coronavirus.
Although with structural similarity to the RING domain, B-box is not necessary for
TRIM/E2 interaction (65). Altogether, the complex domain requirement profiles revealed
for TRIM56-mediated inhibition of distinct RNA viruses illustrate a remarkable example
of host restriction factor evolution, and explain why this TRIM is able to protect cells
from invasion by a broad range of positive-strand RNA viruses.
Last but not the least, I discovered that TRIM56 restricts flaviviruses and HCoVOC43 by targeting distinct stages of the viral life cycle. Time-course intracellular viral
RNA quantification data (Figures 3-10A and 3-10B) suggest that virus-cell receptor
interaction or early cellular entry of these viruses was not affected, while accumulation of
intracellular viral RNAs during replication of YFV but not HCoV-OC43 was retarded.
Moreover, transient replicon assay using a DENV2 replicon confirmed that TRIM56
curbs flavivirus RNA replication but not translation (Figure 3-10C). The effect on YFV
and DENV2 thus mirrored with those observed with TRIM56 on BVDV RNA replicons
(34), suggesting that TRIM56 commonly targets viruses in the family Flaviviridae at the
intracellular RNA replication step. However, I cannot fully exclude the impact, if any, of
TRIM56 on virion transport or RNA uncoating of YFV or DENV2 immediately after the
early entry step. By contrast, the data that progeny viral yield but not intracellular viral
RNA abundance was inhibited by TRIM56 during HCoV-OC43 infection point to an
effect on the viral packaging/release stages, which slows down coronaviral spread. Of
note, it has been reported that mouse TRIM56 inhibits HIV release from cells (64),
setting a precedent for the ability of TRIM56 to act on this late step of viral infections.
Although the underlying molecular details remain to be elucidated, the distinct
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mechanisms of action TRIM56 adopts to inhibit flaviviruses and HCoV-OC43 are
consistent with the differential requirements of the C-terminal portions of this TRIM.
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CHAPTER 4. THE C-TERMINAL TAIL OF TRIM56 DICTATES ANTIVIRAL
RESTRICTION OF INFLUENZA A AND B VIRUSES BY IMPEDING VIRAL
RNA SYNTHESIS1
Introduction
Classified within the family Orthomyxoviridae, influenza A and B viruses (IAV and
IBV) are important respiratory pathogens responsible for significant morbidity and
mortality worldwide (12-15). These viruses possess segmented, negative-strand RNA
genomes that are encapsidated with nucleoprotein (NP) and bound with polymerase
proteins, collectively known as viral ribonucleoprotein (vRNP) complexes (14,15). One
striking feature of the influenza virus life cycle is that virus RNA (vRNA) synthesis takes
place in the nucleus (15,20,21). After virion entry, trafficking of incoming vRNPs into
the nucleus is an active process dependent on the nuclear import machinery, followed by
initiation of virus transcription and replication (15). As is the case of most RNA viruses,
replication of influenza viruses is error-prone, generating mutant viruses that can escape
host immune responses and/or antiviral drugs. Despite intense research and antiviral drug
development efforts, options to combat influenza are for the most part limited to those
targeting the viral NA and M2 ion channel, and emergence of drug-resistant viral mutants
is a pressing issue (15). Thus, studies on novel virus-host interactions that alter influenza
virus fitness are warranted and may reveal new targets for therapeutic interventions.
In response to virus assaults including infection by influenza viruses, host cells
employ exquisitely intrinsic mechanisms to fend off the invader. The induction of type I
and type III inteferons (IFNs) represents a major immediate antiviral response in
mammalian cells and is initiated by several classes of pattern recognition receptors
(PRRs) including the Toll-like receptors (TLRs) and retinoic-inducible gene-I (RIG-I)like receptors (1-4). These PRRs engage viral pathogen-associated molecular patterns,
most notably viral RNAs, triggering signaling cascades that culminate in activation of
two critical transcription factors -- interferon regulatory factor 3 (IRF3) and NF-κB,
which play pivotal roles in the transcription of interferons and pro-inflammatory
cytokines/chemokines, respectively (1-4). To circumvent this host defense mechanism,
IAV blocks IRF3 activation by its multifunctional non-structural protein (NS)-1 to cease
IFN production whereas it exploits activated NF-κB to regulate its viral RNA synthesis
and promote inflammation (25,26). In addition to the IFN system, host cells express,
often constitutively, numerous antiviral proteins dubbed restriction factors, which act to
curb different viral infections via distinct mechanisms (5). Among these, tripartite motifcontaining protein (TRIM) family members have recently garnered increasing attention,
with several reported to participate in host defense against IAV (28-31).
____________________________
1

Adapted with permission. Liu B, Li NL, Shen Y, Bao X, Fabrizio T, Elbahesh H,
Webby RJ, Li K. The C-terminal Tail of TRIM56 Dictates Antiviral Restriction of
Influenza A and B Viruses by Impeding Viral RNA Synthesis. J Virol 2016. pii:
JVI.03172-15.
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TRIM family proteins are characterized by a highly conserved N-terminal RBCC
(RING-B box-Coiled coil) motif and are believed to possess E3 ligase activity conferred
by the RING domain. In contrast, TRIM’s C-terminal portions exhibit high variability in
domain structures, based on which they are divided into up to 11 subfamilies (30,31). Of
these, subfamily C-IV members, as exemplified by TRIM25 and TRIM22, harbor SPRY
or/and PRY domains facilitating protein-protein interactions; TRIM-NHL proteins in
subfamily C-VII, such as TRIM32 and TRIM71, possess NHL (NCL-1, HT2A and LIN41)-repeats mediating binding to RNAs/proteins (67). Functionally, TRIMs have been
implicated in a broad array of cellular processes that range from cell growth,
differentiation, oncogenesis, and more recently, to immunity (29,67-69). Of the
immunity-regulating TRIMs reported to date, several play important roles in
orchestrating PRR-mediated signaling cascades in response to viral invasions. A prime
example is TRIM25, which promotes ubiquitination and activation of the PRR RIG-I to
sense IAV infection and induce IFN expression (38). Acting in a different functional
category, several TRIMs exhibit direct antiviral effects. For example, TRIM22 inhibits
IAV by poly-ubiquitinating viral NP and targets it for proteasome-dependent degradation
(33). Notably, both TRIM25 and TRIM22 depend on the RING-type E3 ligase activity to
operate (29).
Recent evidence suggests that TRIM56 (also referred to as T56) is a novel player in
innate antiviral immunity (34,35,39). This TRIM protein belongs to the subfamily C-V
because it lacks a well-characterized domain in the C-terminal half hitherto (28,29).
TRIM56 promotes TLR3- and STING-mediated antiviral signaling pathways towards
IFN induction via E3 Ub ligase-independent and -dependent mechanisms, respectively
(39,58). Additionally, TRIM56 exerts its direct antiviral effects, which are dependent on
its E3 ligase activity, on four positive-strand RNA viruses, including three members of
the family Flaviviridae, i.e., bovine viral diarrhea virus (BVDV), yellow fever virus
(YFV) and dengue virus serotype 2 (DENV2), and a coronavirus, human coronavirusOC43 (HCoV-OC43) (34,35). However, little is known regarding TRIM56’s antiviral
spectrum against negative-strand RNA viruses, especially respiratory viruses such as
influenza viruses, given the fact that TRIM56 is most abundantly expressed in the lung
(34).
In this study I demonstrate that TRIM56 is an intrinsic host restriction factor of
influenza viruses. Intriguingly, this attribute was found to be uncoupled from TRIM56’s
E3 ligase activity and the entire N-terminal TRIM motif was dispensable. Instead, the Cterminal 63 residues were both necessary and sufficient to inhibit replication of both IAV
and IBV. Moreover, I show that TRIM56 impedes influenza virus infection by hindering
viral RNA synthesis by its C-terminal tail portion.
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Results
Ectopic Expression of TRIM56 Inhibits Propagation of IAV and IBV, but Not That
of SeV or hMPV
We had previously shown that TRIM56 is a restriction factor of four positive-strand
RNA viruses, including three members of the Flaviviridae family (BVDV, YFV and
DENV2) and a Coronaviridae family member (HCoV-OC43) (34,35). However, whether
TRIM56 participates in host defense against negative-strand RNA viruses is largely
unknown. VSV (a Rhabadovirus) is the only negative-strand RNA virus that has been
examined to date; the propagation of this virus was not affected by ectopic expression of
TRIM56 (34). In this study, I set out to determine if manipulation of TRIM56 abundance
alters propagation of influenza viruses, which are medically important viruses classified
within the family Orthomyxoviridae.
I first utilized HEK293-FIT-derived cells with tet-inducible expression of N-terminal
HA-tagged TRIM56 (35) to examine the impact of TRIM56 overexpression on IAV. As
shown in Figure 4-1A (left), negligible expression of HA-TRIM56 protein was observed
in these cells when cultured in the absence of tet (-tet) but considerable HA-TRIM56
protein was detected following tet addition to culture medium (+tet) (compare lane 1 vs
2). When infected with influenza A/PR/8/34 virus at an MOI of 0.1, there was abundant
viral NP antigen in -tet cells at 9 hpi (lane 3). However, NP expression was diminished in
cells induced for HA-TRIM56 expression (+tet, lane 4). Consistent with this, progeny
virus titer in supernatants of 293-FIT-T56 +tet cells were significantly decreased as
compared with -tet cells (P < 0.001) (Figure 4-1A, right). This antiviral effect of
TRIM56 persisted at later time points (i.e., 16, 24 and 48 hpi) (Figure 4-1B).
Additionally, MDBK-T56 cells stably expressing Flag-tagged human TRIM56 were
substantially less susceptible to influenza A/PR/8/34 virus than MDBK-Bsr cells that
express a control retroviral vector, as evidenced by substantially reduced intracellular NP
antigen expression (Figure 4-1C, lower right immunoblot panels), ~1-log fewer (P <
0.01) progeny virions yielded in culture supernatants (Figure 4-1C, upper right panel),
and significantly lower percentage of NP-positive cells (Figure 4-1C, left
immunostaining panel). Furthermore, TRIM56’s antiviral effect against IAV was also
observed in U2OS cells stably expressing TRIM56-Flag (U2OS-T56) compared with
control cells (U2OS-Bsr) expressing a control vector (data not shown). To further
corroborate this finding, I knocked down the ectopically expressed human TRIM56 in
MDBK-T56 cells by lentiviral delivery of a TRIM56 shRNA (shT56). As shown in
Figure 4-1D (lower immunoblot panel), TRIM56-Flag expression was reduced by 80%
in the knockdown cells (MDBK-T56 shT56) compared with the control cells (MDBKT56 ctrl) transduced with a scrambled, negative control shRNA, concomitant with a 6fold increase (P < 0.05) in progeny virus production (MOI = 0.5, 24 hpi; Figure 4-1D,
upper panel). Taken together, I conclude that ectopic expression of TRIM56 impedes
IAV propagation. Importantly, this is a reproducible phenomenon, regardless of the
expression system or cell type.
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Figure 4-1. Ectopic expression of TRIM56 hinders propagation of IAV/IBV, but
not infection by hMPV or Sendai virus.
(A) (Left) HEK293-Flp-In T-REx-TRIM56 (293-FIT-T56) cells were cultured without
(lanes 1 and 3, -tet) or with (lanes 2 and 4, +tet) (2 μg/ml) for 48 h, followed by mockinfection (lanes 1 and 2) or infection with influenza A/PR/8/34 (H1N1) virus for 9 h
(MOI = 0.1; lanes 3 and 4). For +tet cells (lanes 2 and 4), they were kept in tet-containing
media until lysed for western blot. Expression of N-terminally HA-tagged TRIM56 was
detected using an anti-HA tag antibody (Invivogen) that does not cross-react with viral
HA of H1N1 influenza A viruses and expression of IAV NP detected by an anti-influenza
A/WSN/33 (H1N1) NP mAb. Actin served as a loading control to demonstrate equal
sample loading. (Right) Progeny virus production in culture supernatants of 293-FIT-T56
cells with or without tet treatment at 9 hours post-infection (hpi) with influenza
A/PR/8/34 virus (MOI = 0.1). (B) Progeny virus production in culture supernatants of
293-FIT-T56 cells cultured with or without tet at 0, 8, 16, 24 and 48 hpi with influenza
A/PR/8/34 virus (MOI = 0.1). (C) (Left side) Immunofluorescence staining of NP (using
anti-influenza A/WSN/33 (H1N1) NP mAb) in MDBK cells stably expressing TRIM56Flag (T56) or a control retroviral vector (Bsr) at 24 hpi with A/PR/8/34 virus (MOI = 5).
(Right side) Progeny virus titer in culture supernatants (upper) and NP and actin
expression (lower) in lysates of infected cells under the same conditions as those on the
left side. (D) (Lower) Immunoblot analysis of ectopically expressed human TRIM56
(using anti-TRIM56 antibody) in MDBK-T56 cells transduced with lentiviruses encoding
either an shRNA specifically targeting human TRIM56 (MDBK-T56 shT56) or a nontargeting, scrambled control shRNA (MDBK-T56 Ctrl). (Upper) Progeny virus titers in
culture supernatants of the indicated cells infected with influenza A/PR/8/34 virus for 24
h (MOI = 0.5). (E) (Upper) Progeny virus production in culture supernatants of 293-FITT56 cells with or without tet treatment at 24 hpi with influenza B/Florida/4/06
(Yamagata) virus (MOI = 0.1). (Lower) Immunoblot analysis of HA-tagged TRIM56
(using an anti-HA tag mAb (Invivogen) not cross-reacting with IBV HA) and viral HA
(using an anti-influenza B/Hong Kong/8/73 HA pAb). Tubulin served as a loading
control to demonstrate equal sample loading. (F) HeLa-FitA2-T56 cells with tet-regulated
expression of HA-tagged TRIM56 were cultured with (lanes 3 and 4) or without tet (lanes
1 and 2), followed by mock-infection (lanes 1 and 3) or infection by hMPV (MOI = 1,
lanes 2 and 4) for 15 h. Cell lysates were subjected to immunoblot analysis of HA-tagged
TRIM56 (using anti-HA tag mAb (clone 12CA5, Roche)) and viral proteins (using antihMPV pAb). Asterisk denotes a nonspecific band. (G) 293-FIT-T56 cells cultured in the
absence (-tet) or presence (+tet) of tetracycline were infected with Sendai virus (SeV) at
indicated doses (1.6, 16 and 160 HAU/ml) for 8 h, followed by immunoblot analysis of
HA-tagged TRIM56 (using anti-HA mAb (Invivogen)) and viral proteins (using anti-SeV
pAb, which mainly reacted with SeV hemagglutinin-neuraminidase and nucleocapsid).
Actin served as a loading control. Single, double and triple asterisks indicate that
statistical differences exist between the indicated cells with a P value of < 0.05, < 0.01
and < 0.001, respectively.
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I next investigated if TRIM56’s antiviral effect could be extended to IBV. It was
found that induction of TRIM56 expression in 293-FIT-T56 cells led to a sharp decline in
viral HA antigen abundance as compared with -tet (uninduced) cells at 24 hpi with
influenza B/Florida/4/06 virus (MOI = 0.1) (Figure 4-1E, lower panel). Concordant with
this, progeny virus production in +tet cells was 7-fold (P < 0.05) lower than in -tet cells
(Figure 4-1E, upper panel). Similar anti-IBV effect of TRIM56 overexpression was also
observed at 8 and 12 hpi (MOI = 0.01) in HeLa-FitA2-T56 cells with tet-inducible
expression of HA-TRIM56 (data not shown), again confirming that the phenomenon was
not cell-type specific. Collectively, it was established that TRIM56, when ectopically
expressed, curbs IBV infection. Of note, influenza viruses (IAV and IBV) represent the
first negative-strand RNA virus family TRIM56 was found to inhibit.
To determine whether TRIM56 also restricts other negative-strand RNA viruses, I
studied the effects of TRIM56 overexpression on hMPV (Figure 4-1F) and SeV
(Figure 4-1G), paramyxoviruses that cause respiratory infections in humans and rodents,
respectively. There was no inhibitory effect on viral protein expression following
infection by either virus, when comparing cells induced for HA-TRIM56 expression and
uninduced cells. The lack of an antiviral effect on these paramyxoviruses suggests that
TRIM56 does not target negative-strand RNA viruses indiscriminately. Consistent with
this concept, we previously demonstrated that TRIM56 overexpression does not inhibit
VSV propagation (34).
Knockdown of TRIM56 Augments Multiplication of Influenza Viruses
To determine whether TRIM56 expressed at physiologic levels poses a barrier to
infection by influenza viruses, I dissected the effect of TRIM56 knockdown on influenza
virus propagation. Compared to control MDBK cells, MDBK-T56i cells with stable
knockdown of endogenous TRIM56 (34; Figure 4-2A, left) supported substantially
higher levels of viral NP expression and produced >1-log more (P < 0.01) progeny
influenza A/PR/8/34 virions (Figure 4-2A, middle). In contrast, MDBK-T56i cells were
not more permissive than control MDBK cells to infection by VSV-Luc, a recombinant
VSV expressing luciferase as readout of viral replication (Figure 4-2A, right). These
data lend further support to the notion that endogenous TRIM56 specifically hinders
influenza virus infection. The same can be said regarding the impact of TRIM56
depletion on IAV infection in HeLa cells (Figure 4-2B). I found that HeLa cells with
stable knockdown of TRIM56 (shT56) yielded ~6-fold (P < 0.01) more progeny IAV
than control cells. HeLa-shT56 cells also supported higher levels of viral HA protein
expression (Figure 4-2C, immunoblot panels) and ~1-log more (P < 0.01) progeny
influenza virus production (Figure 4-2C, upper panel) than did control cells, following
IBV infection. Altogether, these data demonstrate that TRIM56 expressed at
physiological levels puts a check on infection by influenza A and B viruses.
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Figure 4-2. TRIM56 knockdown augments influenza virus multiplication.
(A) (Left part) qPCR analysis of bovine TRIM56 (boT56) mRNA expression in control
MDBK cells (Ctrl) and its derived cells (T56i) stably transfected with a boT56 shRNA.
(Upper, middle part) Progeny virus production in culture supernatants of MDBK-Ctrl and
MDBK-T56i cells at 24 hpi with influenza A/PR/8/34 virus (MOI = 5). (Lower, middle
part) Immunoblot analysis of NP and actin expression in cell lysates under the conditions
of the upper part. (Right part) MDBK-Ctrl cells and MDBK-T56i cells were infected with
VSV-Luc at MOI of 0.2. At the indicated times, cells were lysed for firefly luciferase
assay. (B) (Lower) Immunoblot analysis of human TRIM56 expression (using antiTRIM56 antibody) in HeLa-plkO.1 (Ctrl) cells stably transduced with a non-targeting,
scrambled control shRNA or HeLa-shT56 (shT56) cells transduced with an shRNA
specifically targeting TRIM56. (Upper) Progeny virus production in culture supernatants
of the two cell lines at 8 hpi with influenza A/PR/8/34 virus (MOI = 0.01). (C) (Lower)
Immunoblot analysis of TRIM56 expression (using anti-TRIM56 antibody) and viral HA
levels (using anti-influenza B/Hong Kong/8/73 HA pAb) in HeLa-plkO.1 (Ctrl) or HeLashT56 (shT56) cells at 8 hpi with influenza B/Florida/4/06 virus (MOI = 0.01). (Upper)
Progeny virus production in culture supernatants of the cells under the same conditions as
the lower immunoblot panel. Double asterisks indicate that statistical differences exist
between the indicated cells with a P value of < 0.01.
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The C-terminal Tail of TRIM56, but Not Its E3 Ligase Activity or the Other
Portions of the Protein, Is Required for the Ability to Impede Influenza Virus
Infection
TRIM56 exerts antiviral actions against positive-strand RNA viruses of distinct
families via overlapping and distinct molecular determinants (34,35). Specifically, while
the TRIM56’s RING and the E3 ligase activity conferred by this domain are required to
inhibit BVDV, flaviviruses and HCoV-OC43, the C-terminal portion (residues 621-755)
is critical for restriction of BVDV and flaviviruses but dispensable for HCoV-OC43
suppression (34,35). To determine which domains or portions of TRIM56 are required for
its novel antiviral actions against negative-strand RNA viruses, I mapped the TRIM56
molecular determinants which are essential for the restriction of influenza viruses, using
HEK293-FIT-derived cell lines with tet-inducible expression of a series of HA-tagged
TRIM56 mutants. The mutants included for analysis were the E3 Ub ligase-deficient
CC21/24AA mutant, mutants lacking the RING (ΔRING), B-box (ΔB-box) or Coiledcoil (ΔCoiled-coil) domains, respectively, and mutants possessing different deletions in
the C-terminal portion -- Δ355-433, Δ621-695 and Δ693-750 (Figure 4-3A, left). The
expression levels of these mutants have been confirmed to be comparable to that of wildtype (WT) TRIM56 (35).
When challenged with the influenza A/PR/8/34 virus at MOI of 0.1, an obvious
inhibitory effect on influenza NP accumulation following tet induction (+tet) was
observed at 9 or 27 hpi in HEK 293-FIT-T56 cells and in all of the mutant TRIM56inducible cells except the line that expresses the Δ693-750 mutant (Figure 4-3B). In
agreement with the influenza NP immunoblot data, progeny virus production was
curtailed by ~1-log by induction of WT TRIM56 (P <0.001) or any of the TRIM56
mutant (P < 0.01), with the exception of the Δ693-750 mutant (Figure 4-3A, right).
Thus, the very C-terminal tail portion of TRIM56 contains the sole determinant crucial
for the anti-IAV activity. In stark contrast with what is required for flavivirus and
coronavirus restriction, the E3 ligase activity of TRIM56 is dispensable for containing
IAV.
To confirm the important findings which were shown above, I made effort to gauge
influenza NP expression and progeny virus production in MDBK cells stably expressing
Flag-tagged, WT or mutant human TRIM56 following infection by influenza A/PR/8/34
virus. As shown in Figure 4-3C (immuoblot data in lower panels), at 13 hpi (MOI = 3),
abundant influenza NP antigen was detected in MDBK-Bsr cells expressing a control
vector (lane 1). However, there was profound reduction in influenza NP expression in
cells expressing WT TRIM56 (lane 3), the E3 Ub ligase-null CC21/24AA mutant (lane
4), ΔRING (lane 5) and ΔCoiled-coil (lane 6) mutants. In contrast, influenza NP
expression was not reduced, but increased (lane 7) as compared with parental MDBK
cells (lane 2). Progeny influenza virus titer data (Figure 4-3C, bar graph in upper panel)
were in accordance with the influenza NP immunoblot results. Collectively, the data
gleaned from MDBK-derived cells mirrored those obtained from HEK 293-FIT-derived
cells.
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Figure 4-3. The restriction of IAV by TRIM56 relies on its C-terminal tail
portion, but not on its E3 ligase activity or other parts of the protein.
(A) (Left) Schematic representation of TRIM56 protein domains and the individual
TRIM56 mutants investigated in this study. (Right) Progeny virus production in culture
supernatants of 293-FIT-T56-WT or individual TRIM56 mutant cells cultured in the
absence (-tet) or presence (+tet) of tet at 9 hpi with influenza A/PR/8/34 virus (MOI =
0.1). (B) Immunoblot analysis of HA-tagged wild-type (WT) or mutant (mut) TRIM56
(using an anti-HA tag Ab (Invivogen) not reacting with viral HA of H1N1 IAV) and NP
protein abundance (using anti-influenza A/WSN/33 (H1N1) NP mAb) in 293-FIT-T56
WT/Mut cells in the absence (odd numbered lanes) or presence (even numbered lanes) of
tet, and mock-infected or infected with influenza A/PR/8/34 virus (MOI = 0.1) for 9 or 27
h. Data from each cell line are presented in an immunoblot block (8 blocks in total,
representing 8 different WT/mut TRIM56-inducible cell lines as shown in panel A). (C)
(Lower) Immunoblot analysis of TRIM56 (using anti-human TRIM56 antibody) and NP
protein abundance (using anti-influenza A/WSN/33 (H1N1) NP mAb) in parental MDBK
as well as MDBK-derived cells stably expressing a control vector (Bsr), C-terminal Flagtagged human TRIM56 (WT) or its mutant versions infected with influenza A/PR/8/34
virus for 13 h (MOI = 3). (Upper) Progeny viral titers in culture supernatants of the
indicated MDBK-derived cell lines infected with influenza A/PR/8/34 virus (MOI = 3)
for 13 h. Double and triple asterisks indicate that statistical differences exist between
MDBK and WT/Mut T56 over-expressing cells, or between -tet and +tet cells with a P
value of < 0.01 and < 0.001, respectively.
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Consistently similar results were obtained when I determined progeny IBV
production in HEK293-FIT-derived cells conditionally expressing WT TRIM56 or
individual TRIM56 mutants (Figure 4-4). The ~1-log reduction in progeny virus yields
(P values ranging from < 0.05 to < 0.001) in + tet cells compared with -tet cells at 24 hpi
with the B/Florida/4/06 virus (MOI = 0.1) was abrogated only in cells harboring the
Δ693-750 mutant. Altogether, the domain-mapping experiments in HEK293-FIT- and
MDBK-derived cells reached the same conclusion that the very C-terminal tail region
contains the sole prerequisite for TRIM56’s antiviral activity against IAV and IBV. The
shared TRIM56 determinant in restricting both genera of influenza viruses is consistent
with the similar replication strategies of these orthomyxoviruses, and suggests that
TRIM56 adopts the same antiviral mechanism against IAV and IBV.
TRIM56’s C-terminal Tail Is Sufficient to Curb Influenza Virus Infection
Since our data showed that residues 693-750 at the C-terminal tail portion of TRIM56
is essential for the anti-influenza function, I asked if peptides derived from TRIM56’s Cterminal region are sufficient to confer influenza virus restriction. To this end, I
established HEK293-FIT-derived cell lines with tet-inducible expression of HA-tagged
TRIM56 fragment comprising the C-terminal 135 (i.e., aa 621-755, referred to as
CTT135) and 63 (i.e., aa 693-755, referred to as CTT63) residues, respectively
(Figure 4-5A-B). When infected with A/PR/8/34 virus (MOI = 0.1), induction of
CTT135 expression led to substantial decline in NP expression and progeny virus
production, which mirrored the effect of induction of TRIM56 expression (Figure 4-5C).
Induction of CTT63 produced a similar effect on NP expression (Figure 4-5D),
suggesting the 63 residues at the very C-terminal end of TRIM56 contain the minimal
determinant for the antiviral function of the full-length protein. The same could be said
when I infected cells with B/Florida/4/06 virus (Figure 4-5E). The shared TRIM56
determinant governing the inhibitory effect on IAV and IBV implies that TRIM56 likely
restricts both genera of influenza viruses via a similar mechanism. Thus, in subsequent
experiments I utilized IAV to probe how TRIM56 executes its anti-influenza actions.
TRIM56 Curtails Influenza Virus Propagation by Targeting Virus RNA Synthesis
Following virus entry and uncoating steps, incoming influenza vRNPs are first
transported into the nucleus, where viral RNA replication occurs (15,20,21). Directed by
a trimeric viral RNA polymerase complex in association with NP, vRNAs serve as the
templates for synthesis of mRNAs and cRNAs, with the latter becoming the templates for
synthesis of progeny vRNAs. Viral mRNAs are then transported to the cytoplasm for
translation into nascent viral proteins that are required for cRNA and vRNA synthesis
(e.g., NP) and that serve structural and regulatory functions. At late stage of the infection,
vRNAs are exported out of the nucleus for virion packaging and budding (15,26). To
determine at which step(s) of the influenza viral life cycle TRIM56 acts, I performed
single-cycle growth analysis of IAV infection. MDBK-T56 cells with stable expression
of human TRIM56 and MDBK-Bsr cells (expressing the empty vector) were infected
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Figure 4-4. TRIM56’s C-terminal tail is the only prerequisite for its anti-IBV
function.
Progeny virus production in culture supernatants of 293-FIT-derived, T56 WT or
individual mutant cells in the absence (-tet) or presence (+tet) of tet at 24 hpi with
influenza B/Florida/4/06 virus (MOI = 0.1). Single and triple asterisks indicate that
statistical differences exist between -tet and +tet cells with a P value of < 0.05 and <
0.001, respectively.
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Figure 4-5. Expression of TRIM56’s C-terminal tail alone is sufficient to curb
infection by IAV or IBV.
(A) Schematic representation of putative NHL-like repeats in TRIM56’s C-terminal
portion and two peptides derived from TRIM56’s C-terminal tail (CTT), i.e., TRIM56’s
C-terminal 135 residues (CTT135) and 63 residues (CTT63). (B) Immunoblotting HAtagged WT TRIM56, CTT135 and CTT63 (using anti-HA tag mAb (Invivogen)), and
actin in HEK293-Flp-In T-REx-derived cells with tet-inducible expression of HA-tagged
WT TRIM56 (293-FIT-T56-WT), CTT135 (293-FIT-T56-CTT135) or CTT63 (293-FITT56-CTT63) in the absence (-tet) or presence (+tet) of tet. (C) (Upper) Progeny virus
titers in supernatants of 293-FIT-T56-WT or -CTT135 cells cultured with (+tet) or
without tet (-tet) at 8 hpi with influenza A/PR/8/34 virus (MOI = 0.1). (Lower)
Immunoblot analysis of NP (using anti-influenza A/WSN/33 (H1N1) NP mAb) and actin
expression in the corresponding cell lysates. (D) Immunoblot analysis of NP (using antiinfluenza A/WSN/33 (H1N1) NP mAb) and actin expression in 293-FIT-T56-WT (left)
or -CTT63 cells (right) cultured with (+tet) or without tet (-tet) at 8 hpi with influenza
A/PR/8/34 virus (MOI = 0.1). (E) (Upper) Progeny virus titers in supernatants of 293FIT-T56-WT or -CTT63 cells cultured with (+tet) or without tet (-tet) at 24 hipi with
influenza B/Florida/4/06 virus (MOI = 0.1). (Lower) Immunoblot analysis of viral HA
(using anti-influenza B/Hong Kong/8/73 HA pAb) and actin expression in the
corresponding cell lysates. Single asterisk indicates that statistical difference exists
between -tet and +tet cells with a P value of < 0.05.
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with influenza A/PR/8/34 virus at an MOI of 3, followed by a stringent wash in 0.9%
NaCl (pH = 2.2) to remove extracellular virions that had not entered the cells. At
1, 4, 8 and 12 hpi, cells were washed extensively with PBS to eliminate extracellular
viruses and viral RNAs before they were lysed for total RNA extraction and qPCR
analysis of intracellular levels of vRNA, cRNA and mRNA of M segment. At the same
time, yields of progeny viruses in cell-free culture supernatants at 8 and 12 hpi were
determined by TCID50 assay.
At 1 hpi, intracellular vRNA levels of A/PR/8/34 virus were indistinguishable
between MDBK-T56 and MDBK-Bsr cells (Figure 4-6A). In line with previous reports
(26,53,70,71), I found at this early time point IAV had already initiated mRNA
transcription and cRNA synthesis in MDBK-Bsr cells. However, the abundance of cRNA
(Figure 4-6B) and mRNA (Figure 4-6C) was 3-fold and 7-fold lower, respectively, in
MDBK-T56 cells, suggesting that viral mRNA transcription and cRNA synthesis were
hindered in TRIM56-overexpressing cells. At 4 hpi when viral RNA synthesis occurs at a
high rate (26,70,71), the abundance of vRNA rose by 5-fold compared to that at 1 hpi
(Figure 4-6A), while cRNA (Figure 4-6B) and mRNA (Figure 4-6C) both climbed by
>3 logs in MDBK-Bsr cells. In contrast, vRNA levels did not increase in MDBK-T56
cells at 4 hpi, suggesting onset of vRNA synthesis was delayed (Figure 4-6A). Although
cRNA and mRNA levels increased compared to 1 hpi, they were 61-fold and 88-fold
lower, respectively, than those in MDBK-Bsr cells (Figure 4-6B-C). At 8 hpi when virus
RNA synthesis had already finished (26,71), I found that levels of all three RNA species
reached plateau in MDBK-Bsr cells as well in MDBK-T56 cells (as compared to 12 hpi).
Nonetheless, vRNA, cRNA, or mRNA levels remained 4-7 fold lower in MDBK-T56
cells at both 8 and 12 hpi (Figure 4-6A-C). These data show that there is a sustained
influence on influenza virus vRNA, cRNA and mRNA levels throughout the life cycle in
TRIM56-overexpressing cells.
In the same experiments (at 8 and 12 hpi), I found that progeny virus production in
MDBK-T56 cells was significantly reduced compared with MDBK-Bsr cells, and the
extent of reduction was proportional to the decrease in vRNA synthesis (data not shown),
indicating that the effect on viral RNA synthesis is primarily responsible for TRIM56’s
anti-influenza action. Confirming that this observation is not cell-type specific, I obtained
similar results when comparing time-course IAV RNA synthesis and progeny virus
production between U2OS-T56 and U2OS-Bsr cells (data not shown). Therefore, it is
confirmed that TRIM56 can curb influenza RNA synthesis in different cell types.
The C-terminal Tail of TRIM56 Is Both Required and Sufficient for the
Suppression of Influenza Virus RNA Synthesis
To corroborate that TRIM56 impedes influenza virus RNA synthesis, I performed a
luciferase reporter-based minigenome replication assay to measure IAV transcription and
replication in HEK293-FIT-T56 cells with (+tet) and without (-tet) induction of HAtagged TRIM56. This system involves co-transfection of a total of six plasmids. Influenza
RNA polymerase subunits (PB2, PB1, and PA) and NP derived from A/PR/8/34 virus are
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Figure 4-6. TRIM56 hinders IAV propagation by inhibiting intracellular virus
RNA synthesis.
qPCR analysis of vRNA (A), cRNA (B) and mRNA (C) levels of matrix (M) gene
segment of influenza A/PR/8/34 virus in MDBK cells stably expressing a control vector
(Bsr) or TRIM56 (T56) at 1, 4, 8 and 12 hpi (MOI = 3). Single, double and triple
asterisks indicate that statistical differences exist between Bsr and T56 cells with a P
value of < 0.05, < 0.01 and < 0.001, respectively.
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expressed from individual plasmids under control of a Pol II promoter. In a fifth plasmid,
the Pol I promoter controls transcription of the antisense strand of Firefly luciferase RNA
flanked by the untranslated regions of M segment vRNA (42). A sixth plasmid, pCMVRL, expresses Renilla luciferase from the CMV promoter, serving as an internal control
for normalization of transfection efficiency. Since this assay was designed to mimic IAV
transcription and replication steps, the Firefly/Renilla luc ratio (i.e., relative luciferase
activity) is proportional to the level of influenza virus RNA synthesis (42,53,54). I found
that at both 24 and 48 h post transfection (hpt), relative luciferase activity was
consistently 2-fold higher (P < 0.01) in -tet cells than in +tet cells (Figure 4-7A),
corroborating the qPCR data on vRNA levels (Figure 4-6) and lending further support
for the notion that TRIM56 inhibits influenza virus RNA synthesis. Additional
minigenome replication assays in Δ693-750 mutant TRIM56-inducible cells and its
parental HEK293-FIT (Ctrl) cells (Figure 4-7B, 48 hpt) showed that this C-terminal tail
deletion mutant loses the ability to suppress influenza viral RNA synthesis and ruled out
any effect due to tetracycline treatment. Further, expression of the CTT63 alone was
sufficient to inhibit influenza viral RNA synthesis (Figure 4-7C), demonstrating that the
C-terminal tail of TRIM56 dictates the antiviral restriction of influenza viruses by
hindering the viral RNA synthesis step.
TRIM56 Moves into the Nucleus during Influenza Infection
Because TRIM56 is a cytosolic protein in resting cells (34), I wondered how this
protein impacts influenza virus RNA synthesis, which takes place in the nucleus. To
address this question I determined the subcellular localization of GFP-TRIM56 in
transiently transfected HeLa cells prior to and after A/PR/8/34 virus infection. As shown
by the representative confocal fluorescence microscopy images (Figure 4-8A), while
GFP-TRIM56 resided exclusively in the cytoplasm of mock-infected cells, GFP-TRIM56
fluorescence was detected in both cytoplasm and nucleus in IAV-infected cells at
different time points post infection. Interestingly, the subcellular distribution pattern of
HA-tagged TRIM56-CTT63 mirrored that of full-length, HA-tagged TRIM56
(Figure 4-8B). While there was no appreciable nuclear immunostaining of CTT63 in
uninfected cells, a fraction of CTT63 was reproducibly found in the nucleus after IAV
infection. The presence of TRIM56 and TRIM56-CTT63 in the nucleus of IAV-infected
cells is consistent with their ability to impede influenza viral RNA synthesis.
Discussion
In this study, I have shown that TRIM56 is an intrinsic host restriction factor of
influenza A and B viruses (Figure 4-1 and 4-2), expanding the antiviral spectrum of this
TRIM to include the Orthomyxoviridae family of segmented, negative-strand RNA
viruses. Ectopic expression of TRIM56 impeded propagation of these medically
important respiratory pathogens (Figure 4-1), while silencing of endogenous TRIM56
expression had the opposite effect (Figure 4-2). Importantly, these findings were
reproduced in multiple cell types, irrespective of the expression system. Moreover, the
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Figure 4-7. The C-terminal tail portion is required for TRIM56 suppression of
influenza virus RNA synthesis.
(A) Luciferase (luc) reporter-based minigenome replication assay of IAV RNA synthesis
was performed in 293-FIT-T56 cells cultured in the presence (+tet) or absence (-tet) of tet
at 24 and 48 h post co-transfection (hpt) with polymerase II-driven pHW plasmids
expressing PB2, PB1, PA and NP, a polymerase I-driven luc reporter plasmid pHY-Luci,
and a CMV promoter-driven plasmid expressing the Renilla luc (pRL-CMV, serving as
an internal control for normalization of transfection efficiency). (B) Luciferase reporterbased minigenome replication assay of IAV RNA synthesis in parental 293-FIT (Ctrl),
293-FIT-T56 (WT), or 293-FIT-T56-Δ693-750 (Δ693-750) cells cultured with (+tet) or
without tet (-tet) at 48 hpt. (C) Luciferase reporter-based minigenome replication assay of
IAV RNA synthesis in 293-FIT-T56 (WT) or 293-FIT-T56-CTT63 (CTT63) cells
cultured with (+tet) or without tet (-tet) at 48 hpt. Double and triple asterisks indicate that
statistical differences exist between -tet and +tet cells with a P value of < 0.01 and <
0.001, respectively.
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Figure 4-8. TRIM56 and TRIM56-CTT63 move into the nucleus after IAV
infection.
(A) HeLa cells transiently transfected with an N-terminal GFP-tagged TRIM56 (GFPT56) plasmid was mock-infected or infected with influenza A/PR/8/34 virus for 4, 8 and
16 h (MOI = 3), followed by immunostaining of NP (using anti-influenza A/WSN/33
(H1N1) NP mAb). The subcellular localizations of GFP-T56 (green fluorescence) and NP
(red fluorescence) were examined by confocal microscopy. Nuclei were counterstained
blue with DAPI (4',6-diamidino-2-phenylindole). A scale bar represents 10 μm. (B) 293FIT-T56 or 293-FIT-T56-CTT63 cells were cultured in the presence of tet to induce
expression of HA-tagged, TRIM56 (WT) or TRIM56-CTT63, followed by mock
infection or infection with influenza A/PR/8/34 virus for 16 h (MOI = 3). HA-tagged
TRIM56 and TRIM56-CTT63 were immunostained with an anti-HA tag mAb
(Invivogen), and IAV matrix (M) proteins with a goat anti-matrix antiserum. The
subcellular localization of HA-tagged WT TRIM56 and TRIM56-CTT63 (green
fluorescence) and M (red fluorescence) proteins was examined by confocal microscopy.
Nuclei were counterstained blue with DAPI. Scale bars represent 5 μm.
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antiviral effect was specific for influenza viruses since TRIM56 did not inhibit SeV or
hMPV (Figure 4-1), paramyxoviruses that cause respiratory infections in mice and
humans, respectively. To our knowledge, this is the first study that demonstrates TRIM56
targets negative-strand RNA viruses for inhibition.
TRIM56 positively regulates innate antiviral signaling through TLR3- and STINGdependent pathways. Specifically, TRIM56 forms a complex with TRIF, the TLR3
adaptor, via its C-terminal region, promoting IRF3 activation and subsequent IFN
response in ways independent of its E3 ligase activity (39). In contrast, the mechanism
underlying the augmentation of STING-dependent IFN-induction pathway is distinct. In
this case TRIM56 associates with STING and acts as an E3 ligase that promotes Lys63linked ubiquitination of STING, thereby enhancing cytosolic DNA-induced IFN
production (58). In previous studies (34,35) we have shown that a heightened IFN
response is not responsible for TRIM56-mediated inhibition of four positive-strand RNA
viruses, BVDV, YFV, DENV2 or HCoV-OC43. This may be also the case for the novel
anti-influenza activity of TRIM56 described in this study. First, I found no evidence of
IFN induction or upregulation of ISGs in all cell types examined in this study following
IAV (A/PR/8/34) infection, regardless of TRIM56 expression status (data not shown).
This was not surprising given that IAV encodes multiple IFN antagonists, with NS1
being the most potent and characterized one (25,72). Second, in cell culture innate
antiviral response to IAV is primarily mediated by RIG-I while TLR3 plays a more
proinflammatory role (22,73). However, TRIM56 does not contribute to or regulate RIGI/MDA5 signaling (39). Third, although STING-dependent pathway significantly
contributes to host defense against DNA viruses and bacterial infections, direct evidence
for this pathway in fending off RNA virus infections is lacking (58,62). Also, it is worth
noting that I demonstrated the anti-influenza effect of TRIM56 in cell lines derived from
HEK293 cells, which have undetectable STING protein expression (35).
Of >70 TRIMs, two (TRIM22 and TRIM32) have been shown to inhibit influenza
virus. Both critically hinge on the E3 ligase activity to operate by promoting viral protein
degradation, with TRIM22 targeting NP (33) while TRIM32 acting on PB1 (74).
However, TRIM56’s anti-influenza mechanism is distinct, which appears to be
completely uncoupled from the E3 ligase activity and does not require the RING, B-box,
or coiled-coil domains, either (Figure 4-3 and 4-4). This E3 ligase-independent
mechanism is also in stark contrast to what is known about the antiviral activities of
TRIM56 against flaviviruses and HCoV-OC43 (35). Remarkably, a TRIM56 fragment of
as few as 63 residues at the C-terminus of the protein recapitulated the anti-influenza
effect imposed by full-length TRIM56 (Figure 4-5), indicating that a fully functional
motif mediating influenza virus restriction is encoded by this small portion of the protein.
Given its small footprint, this anti-influenza determinant may be amenable to therapeutic
manipulations. Additional, refined mapping and codon optimization may lead to a
TRIM56-derived peptide/small molecule that has broad activity against different
influenza viruses, since both IAV and IBV are susceptible to TRIM56’s action.
Our time-course viral RNA quantification data (Figure 4-6) and influenza
minigenome replication assay (Figure 4-7) show that TRIM56 specifically inhibits
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influenza viral RNA synthesis by its C-terminal tail portion. Consistent with the fact that
influenza viral RNA synthesis occurs in the nucleus, I found that a fraction of TRIM56
localized into the nucleus in IAV-infected cells, in contrast with the exclusively cytosolic
distribution of TRIM56 in uninfected cells (Figure 4-8). However, it is unknown whether
the nuclear translocation of TRIM56 following influenza virus infection is an active,
coordinate cellular process to combat the virus, or that TRIM56 is passively imported
into or retained in the nucleus while it is associated with viral RNPs or host factors
recruited to the RNPs. Further studies will be required to clarify this. Interestingly,
TRIM32, which is another IAV-inhibitory TRIM, translocates to the nucleus following
IAV infection as a result of its association with and retention by viral PB1 protein (74). In
addition, a search using the NCBI conserved domain database showed that there exists
sequence homology between the C-terminal residues 521-748 of TRIM56 and the NHL
repeats of several well-characterized TRIM-NHL proteins (TRIM2, TRIM3, TRIM32
and TRIM71) (Figure 4-9) (75,76). Of note, some of these TRIM-NHL proteins have the
ability to regulate RNA abundance and metabolism (75,76), raising the possibility that
TRIM56 might bear a similar function. Further investigation is still required to elucidate
precisely how TRIM56 hinders influenza virus RNA synthesis, knowledge of which will
provide new insights into factors and molecular interactions that control this vital step in
influenza virus life cycle.
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Figure 4-9. Sequence alignment of the C-terminal portion of TRIM56 with the
NHL repeats of well-characterized TRIM-NHL proteins.
The C-terminal amino acid sequence of TRIM56 (GenBank ID: NP_112223) was aligned
and compared with the NHL repeat sequences of the following TRIM-NHL proteins,
including NCL-1 (Swiss-Prot P34611), LIN-41 (Swiss-Prot Q9U489), KIAA0517
(GenBank ID: BAA25443), Brat (GenBank AAF53771), TRIM3 (GenBank ID:
NP_001234936), TRIM2 (GenBank ID: NP_056086) and TRIM71 (GenBank ID:
NP_001034200). The numbering of the repeats in each protein was indicated as blades IVI. Numbers show the beginning (left) and ending (right) positions of each repeat of the
proteins. Resides that are >50% conserved are highlighted by shade in color. Consensus
residues at each conserved amino acid positions across different blades are shown at the
bottom in the consensus sequence, in which “h” represents the hydrophobic residues
isoleucine, leucine and valine. Asterisks denote the stop codon.
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CHAPTER 5. MOLECULAR DETERMINANTS GOVERNING TRIM56MEDIATED POSITIVE REGULATION OF THE TLR3 ANTIVIRAL
SIGNALING PATHWAY
Introduction
In response to viral invasion, the innate immune system constitutes a front line of
host defense armed with multi-layered mechanisms. Of these, pattern recognition
receptors (PRR), such as Toll-like receptors (TLRs) and retinoic-inducible gene-I (RIGI)-like receptors, play important roles in recognizing viral nucleic acids as a major class
of viral pathogen-associated molecular patterns. That recognition triggers intracellular
signaling pathways that culminate in activation of interferon regulatory factor 3 (IRF3)
and NF-κB (1,2). These two transcription factors play pivotal parts in production of
interferons (IFNs) and pro-inflammatory cytokines/chemokines. Type I IFNs (IFN-β and
IFN-α) further induce hundreds of IFN-stimulated genes (ISGs) to establish an antiviral
state restricting viral propagation and spread (1-4).
Over the past decade, TRIM family members as intracellular restriction factors are
increasingly recognized as active players in antiviral innate immunity (28-31).
Structurally, TRIMs possess a highly conserved arrangement of domains in the Nterminal RBCC motif (i.e., RING, B-box and coiled-coil domains), but their C-terminal
tails vary. In general, RING domains confer TRIMs with E3 ubiquitin (Ub) ligase
activity. B-box domains are zinc-binding motifs while coiled-coil domains facilitate selfassociation and oligomerization and act as scaffolds for recruitment and formation of
multi-protein complexes (30,31). Much attention has been paid to delineate direct
antiviral roles of the TRIMs contributing to host restriction of specific types of viruses by
targeting various steps in the viral life cycle. As an example, TRIM22 promotes
polyubiquitination of the NP of influenza A virus (IAV) and targets it for proteasomedependent degradation (33). Work from our group has revealed that TRIM56 is a
versatile antiviral host factor that restricts distinct RNA viruses including human
coronavirus-OC43 and several members of the family Flaviviridae, via overlapping and
distinct molecular determinants, (34,35). I recently found that TRIM56 also restricts
influenza A and B viruses by suppressing viral RNA synthesis via its C-terminal tail,
independent of the E3 ligase activity and other portions of TRIM56 (36).
Recently, the “indirect” antiviral roles of various TRIMs, i.e., through positively
regulating innate antiviral immune signaling pathways and augmenting IFN responses,
have begun to be appreciated. Versteeg et. al reported that approximately half of the 75
TRIMs have the ability to act at different junctures in innate immune signaling pathways,
thereby promoting antiviral responses (37). In this group of TRIMs, TRIM25 depends
upon its E3 ligase activity to ubiquitinate and activate RIG-I, thereby potentiating the
RIG-I-mediated signaling pathway and downstream IFN induction (38,77). As another
example, TRIM56 heightens cytosolic dsDNA-stimulated IFN production by interacting
with and ubiquitinating stimulator of IFN genes (STING), an endoplasmic reticulum
residing adaptor protein for innate immune signaling (58). Interestingly, our lab has
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shown that TRIM56 also promotes viral activation of IRF3 via the TLR3 pathway. In this
case TRIM56 operates independent of its E3 ligase activity or the entire RING domain
but, instead, involves an association with the TLR3 adaptor protein, i.e., TIR-domaincontaining adapter-inducing IFN-β (TRIF), via its C-terminal region (39). However, the
precise mechanism by which TRIM56 positively modulates TLR3 signaling remains
elusive. Also unclear is the detailed TRIM56 determinants governing this property. In
this study, I made efforts to delineate roles of the coiled-coil domain and several putative
phosphorylation sites residing in the C-terminal region of TRIM56 in the up-regulation of
TLR3-dependent antiviral immunity.
Results
TRIM56 Promotes TLR3-mediated, IRF3- or NF-κB-dependent Signaling Pathway
via Forming a Complex with TRIF
We have previously reported that human TRIM56 positively regulates TLR3mediated IRF3-dependent signaling pathway (39). Bioinformatic analysis suggests there
is 81% amino acid (aa) identity between human (here referred to as hTRIM56 or hT56)
and murine TRIM56 (here referred to as mTRIM56 or mT56), though the latter is 22-aa
shorter than the former. I wondered if mTRIM56 would have a similar property as
hTRIM56 for regulating TLR3 signaling. To this end, dsRNA-induced IFN-β promoter
activity with or without ectopic expression of mTRIM56 was determined (Figure 5-1A).
Compared with the control vector, ectopic expression of mTRIM56 enhanced poly-I:Cinduced IFN-β promoter activity by 5.2 folds (P < 0.00001), while at the same time
overexpression of hTRIM56 augmented IFN-β promoter activity by 2.6 folds (P < 0.001,
Figure 5-1A, right). This data suggest that mTRIM56 is a stronger, positive regulator of
TLR3 signaling than hTRIM56.
Previously we found TRIM56 acts at the level of TRIF to modulate the TLR3
signaling pathway. I reasoned that TRIM56 may also influence the activation of NF-κB,
another transcription factor downstream of TRIF in the TLR3 signaling pathway. As
expected, TRIM56 overexpression heightened NF-κB-dependent PRDII promoter
activation following the TLR3 engagement. However, it had no effect on PRDII promoter
activation induced by TNF-α- or IL-1β (Figure 5-1B). Thus, TRIM56 specifically
positively regulates NF-κB activation through TLR3 signaling pathway. This evidence
also confirmed that TRIM56 specifically acts on the TLR3 pathway prior to the
bifurcation of NF-κB and IRF3. Consistent with this, I detected endogenous TRIM56 and
TRIF proteins associated with each other early (0.5 - 2 hours) following exposure to
extracellular poly-I:C, when there was no up-regulation of ISG56 (Figure 5-1C).
Altogether, the aforementioned experiments corroborated that TRIM56 is a positive
regulator of TLR3-mediated IRF3- and NF-κB-dependent signaling via its interaction
with TRIF.
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Figure 5-1. TRIM56 positively regulates TLR3-mediated IRF3- or NF-κBdependent signaling pathway by forming a complex with TRIF.
(A) (Left) Immunoblot analysis of the expression of vectors encoding C-terminally V5tagged mouse TRIM56 (mT56-V5) and human TRIM56 (hT56-V5) (using mouse antiV5 monoclonal antibody (mAb)) in human embryo kidney (HEK) 293 cells. Actin serves
as loading control. (Right) HEK293-TLR3 cells which ectopically express TLR3 were
co-transfected with a plasmid encoding hT56 or mT56, or the corresponding empty
vector (vector), as well as internal control plasmid pRL-TK and reporter plasmid IFN-βluc, followed by mock treatment or treatment with poly-I:C (pIC) for 8 h. Dual luciferase
(luc) reporter assay was then performed to measure the promoter activation. (B) (Left)
Immunoblot analysis of the ectopic expression of N-terminally Flag-HA-tagged TRIM56
(FH-T56) (using mouse anti-HA mAb) in HEK293-TLR3-YFP (293-T3Y)-derived cells
over-expressing FH-TRIM56 (293-T3Y-FH-T56). HEK293-T3Y-FH-T56 and its
parental 293-T3Y cells were co-transfected with internal control plasmid pRL-TK and
reporter plasmid IFN-β-luc (middle), or NF-κB responsive reporter plasmid PRDII-luc
(right), followed by mock treatment or treatment with TNF-α, IL-1β or poly-I:C for 8 h.
Dual luc reporter assay was then performed to measure the corresponding promoter
activation. (C) Co-immunoprecipitation (co-IP) analysis of the interaction between
endogenous TRIM56 with endogenous TRIF in HeLa cells at the indicated time points
post poly-I:C treatment. Cell lysates were immunoprecipitated (IP) with anti-TRIM56
polyclonal Ab (pAb), followed by immunoblotting (IB) with anti-TRIF or anti-TRIM56.
The upper blot showed expression of TRIM, TRIF and IFN-stimulated gene 56 in cell
lysates. Single asterisk indicates that statistical differences exist between mock- and polyI:C-treated cells with a P value of < 0.05. N.S., not statistically significant.
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The Coiled-coil Domain and Residues 431-610 of TRIM56, but Not B-box or
Residues 355-433, Are Critical for Enhancing TLR3-mediated IRF3- or NF-κBdependent Signaling
We have previously demonstrated that TRIM56’s C-terminal end (aa 621-750) is
critical for its positive regulation of TLR3-mediated IRF3-dependent signaling, while the
E3 ligase activity and the entire RING domain are dispensable (39). However, the
contribution of other portions of TRIM56 to this biological process is unknown. To better
understand this, I measured poly-I:C-induced IFN-β promoter activities after transient
expression of WT and various mutant TRIM56-V5 (Figure 5-2A). The mutants studied
in this assay included those lacking the RING domain (referred to as ΔRING), B-box
domain (referred to as ΔB-box), and all (ΔCoiled-coil) or part (Δ211-284 and Δ290-353)
of the coiled-coil domain, respectively, and mutants bearing different deletions in the Cterminal portion – Δ355-433 (lacking aa 355-433), Δ431-519 (lacking aa 431-519),
Δ515-610 (lacking aa 515-610), Δ693-750 (lacking aa 693-750) and Δ369-742 (lacking
aa 369-742). In addition, we examined the Δ2-363 mutant, which lacked residues 2-363
thus losing the entire RBCC motif and a stretch of downstream sequences. The
expression levels of these V5-tagged TRIM56 mutants were comparable to that of WT
TRIM56 (data not shown; 34). Confirming our previous observation (39), the ΔRING
mutant retained the ability to promote TLR3 signaling, acting similarly to WT TRIM56
whereas deletions in the C-terminal end (Δ693-750) abolished TRIM56’s ability to
promote TLR3 signaling (P < 0.01, Figure 5-2A). Consistent with the latter result, the
Δ369-742 mutant bearing a larger deletion in the C-terminal region (i.e., lacking nearly
the C-terminal half of TRIM56) was also devoid of such capability (Fig. 5-2A).
Interestingly, I found that the C-terminal portion of TRIM56 required for positive
regulation of TLR3 signaling also included aa 431-610, since ectopic expression of Δ431519 and Δ515-610, but not Δ355-433, failed to augment TLR3-mediated IFN-β promoter
activation, as compared with WT TRIM56 (P < 0.01), respectively. As to the N-terminal
domains, ΔB-box was found to maintain the ability to enhance poly-I:C-induced IFN-β
promoter activity. In contrast, Δ2-363 lacking the RBCC motif was unable to do so,
suggesting a requirement for the coiled-coil domain. Confirming this notion, deletions of
the entire coiled-coil (ΔCoiled-coil) or part of this domain (Δ211-284 and Δ290-353)
abolished the function of TRIM56 in heightening TLR3 signaling (P < 0.01 to < 0.001).
In aggregate, these data demonstrated that the integrity of the C-terminal portion
spanning aa 431-750 is critical for the ability of TRIM56 to promote TLR3 signaling, as
is the coiled-coil domain. However, the B-box is dispensable. These data were confirmed
by examining TLR3-mediated activation of IFN-β or IL-29 (IFN-λ1) promoters in 293FIT-T56 WT/Mut cells with tet-inducible expression of HA-tagged WT/mut TRIM56
(Figure 5-2B) .
TRIM56 can self-associate to form dimers, and the coiled-coil domain has been
reported to mediate formation of anti-parallel dimers for TRIM molecules (34,66). To
ascertain that the ΔB-box and Δ355-433 TRIM56 mutants are indeed capable of
promoting TLR3 signaling, one has to exclude the possibility that functions of these
mutants are dependent upon their pairing with endogenous, WT TRIM56. Our previous
(36) and current qPCR data (Figure 5-2C, bottom) suggest that the mRNA level of the
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Figure 5-2. TRIM56’s coiled-coil domain and residues 431-610, but not the B-box
or residues 355-433, are required for its augmentation of TLR3-mediated IRF3dependent signaling pathway.
(A) (Left) Schematic representation of wild-type (WT) and various TRIM56 mutants to
be investigated in this study. R, B and CC represent RING, B-box and Coiled-coil
domains, respectively. (Right) HEK293-TLR3 cells were co-transfected with an empty
vector or vectors encoding WT and various mutant TRIM56-V5, as well as internal
control plasmid pRL-TK and reporter plasmid IFN-β-luc, followed by mock- or poly-I:Ctreatment (for 8 h) and dual luc reporter assay. (B) Tetracycline (tet)-inducible HEK293Flp-In-T Rex (FIT)-derived cells conditionally expressing N-terminally HA-tagged, WT
and mutant (mut) TRIM56 (HEK293-FIT-T56 WT/Mut) in the absence (-tet) or presence
(+tet) of tet, were co-transfected with TLR3-encoding vector, pRL-TK and reporter
plasmid IFN-β-luc (upper part) or IL-29-luc (lower part), followed by mock- or poly-I:Ctreatment (for 8 h) and dual luc reporter assay. (C) (Top) Immunoblot analysis of
expression levels of endogenous and exogenously overexpressed (HA-tagged) TRIM56
(using anti-TRIM56) in HEK293-FIT-T56 cells with (+tet) or without (-tet) tet treatment
for 48 h. qRT-PCR was carried out to measure the abundance of endogenous TRIM56
transcript (middle, using primers amplifying the 3’ UTR of TRIM56 mRNA), total
TRIM56 transcript including the endogenous and exogenously overexpressed TRIM56
mRNAs (bottom, using primers amplifying the coding region of TRIM56 mRNA) in 293FIT-T56 cells cultured with (+tet) or without (-tet) tet, and transfected with a negative
control siRNA (Ctrl) or siRNA targeting 3’ UTR of TRIM56 (siT56-UTR). Note that (1)
in -tet cells only endogenous, untagged TRIM56 was detected, while in +tet cells both
forms of TRIM56 were visible. Densitometry analysis of the immunoblotting data show
that the total TRIM56/actin arbitrary units for +tet cells were 12-fold of that for -tet cells;
(2) the siT56-UTR merely silenced the expression of the endogenous TRIM56 transcript
but not that of the exogenously introduced (tet-inducible) TRIM56 which expressed only
the coding region of the gene. (D) HEK293-FIT-T56 WT/Mut cells with (+tet) or without
(-tet) tet were co-transfected siT56-UTR or the negative control siRNA (Ctrl), as well as
a TLR3-encoding vector, pRL-TK and IFN-β-luc, followed by mock- and poly-I:Ctreatment (for 8 h) and dual luc reporter assay. Statistical analysis was performed
between WT TRIM56 and vector or mutant TRIM56 after poly-I:C treatment in (A),
between poly-I:C-treated -tet and +tet cells in (B) or (D), or between ctrl and siT56-UTR
groups in (C) or (D). Single, double and triple asterisks denote that statistical differences
exist with a P value of < 0.05, < 0.01 and < 0.001, respectively. N.S., not statistically
significant.
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exogenously introduced HA-tagged TRIM56 in cells cultured in the presence of tet (+tet)
is ~10-15-fold higher than the endogenous TRIM56 transcript level (in cells cultured in
the absence of tet (-tet)). The protein expression data are in line with the mRNA data, as
shown in Figure 5-2C (top). When I efficiently silenced the expression of endogenous
WT TRIM56 by transfecting cells with an siRNA (siT56-UTR) specifically targeting the
3’ UTR of the endogenous TRIM56 transcript (Figure 5-2C), expression of the ΔB-box
or Δ355-433 mutant was still able to augment poly-I:C-induced IFN-beta promoter
activity (Figure 5-2D). Similar observation was also made when performing this assay
with IL-29-luc (data not shown). These data confirm that the B-box and aa 355-433 are
dispensable for the function of TRIM56 in promoting TLR3-mediated, IRF3-dependent
signaling. I found a similar TRIM56 domain requirement profile for modulation of
TLR3-mediated NF-κB activation (Figure 5-3), which is in agreement with our earlier
finding that TRIM56 acts on the TLR3 pathway prior to the bifurcation of NF-κB and
IRF3.
Putative Phosphorylation Sites S471, S475 and S710 Are Required for TRIM56mediated Positive Regulation of TLR3 Signaling
The C-terminal tail of TRIM56 has been shown to be indispensable for modulation of
TLR3 signaling. Recently I have found there are four conserved serines in the C-terminal
portions of human and murine TRIM56 (Figure 5-4A), which have been identified as
phosphorylation sites in previous global proteomic studies (78-83). Specifically, the
cluster of three putative phosphorylation sites (S469, S471 and S475) and S710 fall into
aa 431-519 and aa 693-750, respectively, regions found to be essential for TRIM56’s
ability to augment TLR3 signaling (Figures 5-2A and 5-3; 39).
To determine if residue S710 plays a role in modulation of TLR3 signaling, vectors
encoding TRIM56-V5 bearing S710A and S710D substitutions, respectively, were
constructed in pCDNA3.1 backbone. These S710 mutants were expressed at comparable
levels to that of WT TRIM56 or Δ693-750 in transfected cells as determined by
immunoblotting (Figure 5-4B). I found that S710A mutation significantly (P < 0.01)
reduced TRIM56-mediated up-regulation of poly-I:C-stimulated IFN-β promoter activity
in HEK293-TLR3 cells to an extent similar to the Δ693-750 deletion, suggesting
TRIM56-S710 is important for positive regulation of TLR3 signaling (Figure 5-4C, left).
Similarly, an alanine mutation (S689A) on mTRIM56-S689, the counterpart of hTRIM56
S710, also significantly impaired mTRIM56’s ability to heighten TLR3 signaling
(Figure 5-4C, right). To further investigate the role of putative phosphorylation on
TRIM56-S710 in regulating TLR3 signaling, I expressed WT TRIM56 and the S710
mutants in HeLa-shT56 093 (clone #9) cells stably transduced with an shRNA
specifically targeting the 3’UTR of TRIM56 transcripts, which were not present in WT
and mutant TRIM56 expression constructs. As shown in Figure 5-4D (left), I confirmed
the knockdown efficiency of endogenous TRIM56 in HeLa-shT56 093 (clone #9) cells
(compare lane 9 with lane 1 or 2). Consistent with this, as shown in Figure 5-4D (right),
poly-I:C-stimulated IFN-β promoter activity significantly diminished in HeLa-shT56 093
cells
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Figure 5-3. TRIM56’s coiled-coil domain and residues 431-610, but not the B-box
or residues 355-433, are critical for its potentiation of TLR3-mediated NF-κBdependent signaling pathway.
HEK293-TLR3 cells were co-transfected with an empty vector or vectors encoding WT
and various mutant TRIM56-V5, as well as internal control plasmid pRL-TK and NF-κB
responsive reporter plasmid PRDII-luc, followed by mock- or poly-I:C-treatment (for 8
h) and dual luc reporter assay. Statistical analysis was performed between WT TRIM56
and vector or mutant TRIM56 after poly-I:C treatment. Double asterisks denote that
statistical differences exist with a P value of < 0.01. N.S., not statistically significant.
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Figure 5-4. Putative phosphorylation on TRIM56’s C-terminal serines S471, S475
and S710 is essential for its positive regulation of TLR3-mediated signaling
pathway.
(A) Schematic representation of four conserved putative phosphorylation sites in human
TRIM56 (S469, S471, S475 and S710) and mouse TRIM56. (B) Immunoblot analysis of
the expression of vectors encoding WT TRIM56-V5 and its S710A, S710D and Δ693750 mutants (using mouse anti-V5 mAb) in HEK293 cells. Actin serves as a loading
control. (C) HEK293-TLR3 cells were co-transfected with an empty vector or plasmids
encoding WT or mutant hT56 (left part) or mT56 (upper right part), as well as internal
control plasmid pRL-TK and reporter plasmid IFN-β-luc, followed by mock treatment or
treatment with poly-I:C for 8 h. Dual luc reporter assay was then performed to measure
the promoter activation. (Lower right) Immunoblot analysis of expression of the vectors
encoding WT mT56-V5 and its mutant S689A. (D) (Left) Immunoblot analysis of
expression level of endogenous TRIM56 (using rabbit anti-TRIM56 pAb) in HeLa cells
or those stably transduced with a non-targeting, scrambled control shRNA (Ctrl), or
HeLa-shT56 cell clones stably transduced with a TRIM56 shRNA (#093) which
specifically targets the 3’UTR region of human TRIM56. Asterisk denotes a nonspecific
band. (Right) HeLa-shT56 cells (clone #9) and its knockdown control cells (Ctrl) were
co-transfected with an empty vector or vectors encoding WT or mutant TRIM56 as well
as internal control plasmid pRL-TK and reporter plasmid IFN-β-luc, followed by mock
treatment or treatment with poly-I:C for 8 h. Dual luc reporter assay was then performed
to measure the promoter activation. (E) (upper part) Human hepatoma Huh7.5-TLR3
cells ectopically expressing TLR3 were co-transfected with an empty vector or vectors
encoding WT or mutant TRIM56 as well as internal control plasmid pRL-TK and
reporter plasmid IFN-β-luc, followed by mock treatment or treatment with poly-I:C (for 8
h) and dual luc reporter assay. (Lower part) Immunoblot analysis of the expression of the
vectors encoding WT TRIM56-V5 and its S469A, S471A or S475A single mutant and
S469A+S471A+S475A triple mutant (using mouse anti-V5 mAb) in HEK293 cells.
Statistical analysis was performed between WT TRIM56 and vector or mutant TRIM56
after poly-I:C treatment. Single, double and triple asterisks denote that statistical
differences exist with a P value of < 0.05, < 0.01 and < 0.001, respectively. N.S., not
statistically significant.
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(clone #9) compared with that in the knockdown control (Ctrl) cells. In HeLa-shT56 093
(clone #9) cells, while the phospho-mimetic TRIM56-S710D mutant exhibited
comparable activity to WT TRIM56 in promoting TLR3 signaling, the TRIM56-S710A
mutant (P < 0.05) had a significantly impaired activity. Similar results were obtained in
control HeLa cells.
Further, alanine screening mutagenesis (Figure 5-4E) suggested the S471A or S475A
single mutant or S469A+S471A+S475A triple mutant failed to enhance TLR3 signaling
(P < 0.05, < 0.001, and 0.01, respectively), while the S469A mutant was only slightly
impaired for such ability (statistically insignificant when compared with WT TRIM56),
supporting a role for putative phosphorylation of TRIM56 at S471 and S475 in promoting
TLR3 signaling. These findings show the importance of putative phosphorylation sites
S710, S471 and S475 in TRIM56-mediated up-regulation of TLR3 signaling.
Alanine Substitutions on the Important TRIM56’s Putative Phosphorylation Sites
and Deletion of the Coiled-coil Domain Undermine the TRIM56-mediated
Enhancement of TLR3-dependent Antiviral Response
I have shown that TRIM56 mutants on the putative phosphorylation sites and the
coiled-coil domain impair TLR3-mediated IFN-β promoter activation, which is critical
for establishment of an antiviral state (39). Next I directly determined the impact of these
mutations on TLR3-mediated establishment of an antiviral state. To this end, I
established HEK293-FIT-derived cell lines with tet-inducible expression of HA-TRIM56
with alanine mutations on TRIM56’s putative phosphorylation sites using the strategy we
chose to create the 293-FIT-T56 cell line. These include cell lines with tet-inducible
expression of S469A, S471A, S475A or S710A single mutant, and
S469A+S471A+S475A triple mutant, respectively. As shown in Figure 5-5A, there was
negligible expression of mutant HA-TRIM56 when these cell lines were cultured in the
absence of tet (Figure 5-5A, odd-numbered lanes, data for S710A (-tet) not shown),
while robust expression of mutant HA-TRIM56 of comparable levels to WT TRIM56 in
HEK293-FIT-T56 cells, was detected in tet-containing medium (Figure 5-5A and lower
panel of Figure 5-5B (including data for S710A +tet cells)). Next, HEK293-FIT-derived
cells conditionally expressing WT and mutant HA-TRIM56 with (+tet) or without (-tet)
tet were reconstituted with Flag-TLR3 by transient transfection of a TLR3-encoding
plasmid (Figure 5-5B, lower), followed by poly-I:C stimulation to induce an antiviral
state and then VSV-luc challenge. In mock-treated cells, regardless of cell type and tet
addition status, VSV-luc replicated with similar efficiency as illustrated by the virusencoded luc activity (Figure 5-5B, upper), which is in line with our previous finding that
TRIM56 itself had no influence on VSV replication (34). Poly-I:C stimulation induced an
antiviral state in the cells without tet (-tet, i.e., no induction of WT or mutant TRIM56) to
similar extent among WT and mutant TRIM56 cell lines, resulting in a ~75% reduction in
VSV-luc replication compared with unstimulated cells. By contrast, WT TRIM56
induction in 293-FIT-T56 (+tet) cells exhibited significantly (P < 0.05) more inhibition of
VSV-luc replication (88%), consistent with our earlier finding that TRIM56 potentiates
the dsRNA-stimulated, TLR3-dependent antiviral response (39). This phenomenon was
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Figure 5-5. TRIM56’s coiled-coil domain and C-terminal putative
phosphorylation sites S710, S471 and S475 are important for the establishment of an
antiviral state by TLR3 ligand.
(A) Generation of HEK293-FIT-derived cells that conditionally express individual
TRIM56 mutants on the putative phopho-sites in a tet-inducible manner. Immunoblot
analysis of expression of WT HA-TRIM56 and various mutant TRIM56 (using mouse
anti-HA mAb) in 293-FIT-T56 WT/Mut cells with (+tet) or without (-tet) tet treatment
for 48 h. Actin serves as a loading control. (B) (Upper) HEK293-FIT-derived cells
conditionally expressing WT HA-TRIM56 and its mutants at the indicated putative
phospho-sites with (+tet) or without (-tet) tet, were reconstituted with TLR3 and mockstimulated or stimulated by poly-I:C, followed by infection with VSV-luc (MOI = 0.1).
At 6 h postinfection, cells were lysed for firefly luciferase assay. (Lower) Immunoblot
analysis of expression of the induced WT and mutant HA-TRIM56 (using mouse anti-HA
mAb) and reconstituted Flag-tagged TLR3 (using mouse anti-flag mAb) in the tested
293-FIT-T56 WT/Mut cells before VSV-luc infection. (C) HEK293-FIT-derived cells
conditionally expressing WT HA-TRIM56 and its coiled-coil domain deletion mutant
(Δcoiled-coil) with (+tet) or without (-tet) tet, were reconstituted with TLR3 and mockstimulated or stimulated by poly-I:C, followed by infection with VSV-luc (MOI = 0.1).
At 4 h postinfection, cells were lysed for firefly luciferase assay. (Lower) Immunoblot
analysis of expression of the induced WT HA-TRIM56 and its ΔCoiled-coil mutant
(using mouse anti-HA mAb) in the tested 293-FIT-T56 WT/ΔCoiled-coil cells before
VSV-luc infection. Statistical analysis was performed between poly-I:C-treated -tet and
+tet cells. Single and double asterisks denote that statistical differences exist with a P
value of < 0.05 and < 0.01, respectively. N.S., not statistically significant.
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also found in TRIM56-S469A expressing cells (+tet) which had 85% decrease in VSVluc replication, suggesting that TRIM56-S469A retains the ability to promote the
TRIM56-TLR3-dependent antiviral response. On the contrary, expression of Δ693-750,
S471A, S475A, S469A+S471A+S475A or S710A mutants failed to promote a poly-I:Cstimulated, TRIM56-TLR3-dependent antiviral response. There was no further
statistically significant decrease in VSV-luc replication in poly-I:C-treated, +tet mutant
cells as compared with poly-I:C-treated, –tet mutant cells (Figure 5-5B, upper). This
could also be said for cells conditionally expressing the Δcoiled-coil mutant, since the
293-FIT- Δcoiled-coil cells cultured in the presence of tet (+tet) lost the ability to
enhance poly-I:C-stimulated antiviral response against VSV-luc (Figure 5-5C). These
observations show TRIM56’s putative phosphorylation sites S471, S475 and S710 and its
coiled-coil domain play critical roles in promoting TLR3-dependent antiviral responses.
TRIM56’s Putative Phosphorylation Site S710 on the C-terminus, but Not the
Coiled-coil Domain, Is Critical for Its Association with TRIF
I next sought to characterize the mechanism(s) by which TRIM56’s putative
phosphorylation site and coiled-coil domain help TRIM56 to promote TLR3 signaling.
TRIM56 was reported to promote TLR3 signaling by forming a complex with TRIF (39).
Given the fact that S710 falls into the region (aa 621-750) responsible for its association
with TRIF, I asked if this putative phosphorylation site is important for TRIM56-TRIF
interaction. Co-IP experiments showed that the S710A mutant abolished the TRIM56TRIF interaction similar to the Δ693-750 TRIM56 mutant (Figure 5-6A). Since the
S710A mutant lost the ability to augment poly-I:C-induced IFN transcription
(Figure 5-4) and host antiviral response (Figure 5-5B), I concluded that TRIM56’s
putative phosphorylation site S710 may affect the TRIM56 interaction with TRIF. Next I
asked if the coiled-coil domain, which was found to be important for positive regulation
of TLR3 signaling was also indispensable for TRIM56-TRIF association. As shown in
the co-IP experiment with 293-FIT-T56 WT/Mut cells (Figure 5-6B), the ΔCoiled-coil
mutant retained the ability to form a complex with TRIF, suggesting that the coiled-coil
domain is not required for the TRIM56-TRIF association. Interestingly, this experiment
also showed that aa 355-433 does not mediate the interaction with TRIF either, since the
Δ355-433 mutant can still interact with TRIF.
Discussion
It has been shown that TRIM56 possesses the ability to promote TLR3-mediated
IRF3-dependent antiviral signaling and IFN induction. Interestingly, TRIM56
knockdown suppressed TLR3-mediated induction of RANTES and IP-10 in hepatitis C
virus (HCV) infected hepatoma cells (39), chemokines that are under coordinate control
of NF-κB and IRF3 (84). The present study directly demonstrates that TRIM56 positively
regulates TLR3-mediated NF-κB activation (Figure 5-1B), in addition to its effect on
IRF3 activation (39). These data suggest that TRIM56 acts at a level prior to the
bifurcation of IRF3 and NF-κB, and are consistent with our previous data showing that
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Figure 5-6. TRIM56’s putative phospho-site S710, but not its coiled-coil domain,
is important for its interaction with TRIF.
(A) Co-IP experiment in HEK293 cells co-expressing Flag-TRIFSA and WT TRIM56-V5
or various mutant TRIM56-V5. Cell lysates were immunoprecipitated (IP) with anti-V5,
followed by immunoblotting (IB) with anti-Flag or anti-V5. The right blot showed
expression of the various TRIM56-V5 (WT or mutant) and Flag-TRIFSA in cell lysates.
(B) Co-IP experiment in HEK293-FIT-T56 WT/mut cells co-expressing Flag-TRIFSA and
WT or various mutant HA-TRIM56 (by addition of tet (+tet)). Cell lysates were
immunoprecipitated (IP) with anti-TRIM56, followed by immunoblotting (IB) with antiFlag or anti-HA. The bottom blot showed expression of the various HA-TRIM56 (WT or
mutant) and Flag-TRIFSA in cell lysates.

76

TRIM56 likely promotes TLR3 signaling by associating with TRIF. As additional
evidence supporting this notion, we show here that endogenous TRIM56 and TRIF
proteins formed a complex at an early stage after TLR3 engagement, prior to induction of
ISG56, an IRF3-target gene (Figure 5-1). The observation that TRIM56 promotes both
IRF3 and NF-κB arms of TLR3 signaling suggests that it may regulate IFN antiviral
responses as well as inflammatory chemokine/cytokine responses activated through this
innate immune pathway.
In this study, I have comprehensively dissected the molecular determinants governing
the ability of TRIM56 to positively regulate the TLR3 signaling pathway. I found that
TRIM56’s coiled-coil domain and an extended C-terminal portion (aa 431-610) are
critical for promoting TLR3 signaling (Figures 5-2 and 5-3), while the B-box and a
central region downstream of the Coiled-coil domain (aa 355-433) are not. Within the
important C-terminal region, I identified three conserved, putative phosphorylation sites,
i.e., S471, S475 and S710, as indispensable for TRIM56-mediated up-regulation of TLR3
signaling (Figure 5-4). Importantly, these findings were observed in different cell types
and expression/silencing systems. Moreover, the effects on IFN promoter activation were
recapitulated by VSV-Luc-based assay directly gauging TLR3-dependent establishment
of an antiviral state. (Figure 5-5). Together, our data reveal novel insights into the
mechanism of TRIM56 augmentation of the TLR3-dependent antiviral response and
highlights a role for TRIM56 scaffolding and phosphorylation in positive regulation of
TLR3 signaling.
In the extended C-terminal region now identified to be required for up-regulation of
TLR3 signaling, aa 515-610 account for half of the NHL-like repeats of TRIM56 (aa
497-754, Figure 4-9), a barrel-like β-propeller structure which may be important for
protein-RNA or protein-protein interaction (36). On the other hand, I found that putative
phosphorylation sites S471 and S475 within aa 431-519 and S710 on the C-terminal end
are important for TRIM56 to potentiate TLR3-dependent IFN-β promoter activation and
establishment of an antiviral state (Figures 5-4 and 5-5). Furthermore, S710A completely
abolished TRIM56-TRIF interaction (Figure 5-6). Others studies of post-translational
modification of TRIMs were focused on ubiquitination due to the fact that TRIMs bear
E3 ligase activity and they tend to catalyze the self-reactions that are believed to be
important for their functions (29,34,37). Recently tyrosine phosphorylation of the E3
ubiquitin ligase TRIM21 has been reported to be critical for TLR3/4-mediated positive
regulation of IRF3 activation and IFN induction (85). Interestingly, ProtScale analysis
indicates that aa 425-475 of TRIM56 is a highly hydrophilic region for TRIM56, which is
in agreement with our prediction that phosphorylation occurs on S471 or/and S475.
This study also demonstrates that the coiled-coil domain is indispensable for TRIM56
promotion of TLR3 signaling (Figures 5-2, 5-3 and 5-5). The coiled-coil domains of
TRIMs have been reported to mediate dimerization of TRIM molecules (66).
Interestingly, I observed that a coiled-coil domain deletion mutant (ΔCoiled-coil) was
still able to associate with TRIF (Figure 5-6B). This suggests that the TRIM56-TRIF
interaction does not require TRIM56 dimerization. Rather, I propose that the TRIM56
coiled-coil domain may serve as a scaffold that recruits and interacts with other important
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signaling components, thereby accelerating signal transduction. However, further
experiments are needed to confirm that the coiled-coil domain is indispensable for
TRIM56 oligomerization. Also, further investigation is still needed to clarify the previse
role of the TRIM56 coiled-coil domain and its possible scaffolding function in positive
regulation of TLR3 signaling.

78

CHAPTER 6.

DISCUSSION

The Distinct Domain Requirements for TRIM56’s Anti-flaviviruses and AntiHCoV-OC43 Actions May Reflect Different Molecular Mechanisms That TRIM56
Adopts to Restrict Different Positive-strand RNA Viruses
In this body of work, I have demonstrated that human TRIM56 is an antiviral host
factor against diverse positive-strand RNA viruses. Specifically, TRIM56 exhibits
antiviral activities against two medically important flaviviruses (YFV and DENV2) and a
human coronavirus (HCoV-OC43) (Figures 3-1 and 3-2). Further, I have shown that the
E3 ligase activity is a shared requirement for the antiviral actions of TRIM56 against the
two flaviviruses and HCoV-OC43, and that while dispensable for restricting HCoVOC43, the integrity of the C-terminal portion of TRIM56 is additionally required for the
anti-flavivirus functions (Figures 3-6, 3-7 and 3-9). I also found that TRIM56 suppresses
intracellular viral RNA replication of yellow fever and dengue viruses but may target the
packaging or release steps in HCoV-OC43 life cycle (Figure 3-10).
The findings concerning the differing domain requirements for the novel antiviral
actions of TRIM56 suggest differences in the antiviral mechanisms against different
viruses. By virtue of the E3 ligase activity, TRIM56 might modulate posttranslational
modification(s) of one or more viral proteins and host factors to suppress positive-strand
RNA virus replication (34). Given its broad antiviral activities against positive-strand
RNA viruses, I favor the hypothesis that host factors are involved. The target proteins for
TRIM56 E3 ligase during infections with flaviviruses (YFV and DENV) and HCoVOC43 will need further studies. TRIM56 promotes ubiquitination (34), the best-known
enzymatic activity for most TRIMs (29,31,77,86). It is not known, however, how this
modification of the target proteins may be responsible for the antiviral effects, including,
but not limited to, promoting their degradation or altering their intracellular trafficking. It
is also possible that TRIM56 antiviral function works by promoting Ub-like
modifications such as sumoylation and ISGylation, as demonstrated with TRIM28 and
TRIM25 (87,88).
Moreover, the dichotomy in the molecular determinants governing TRIM56’s antiflaviviruses and anti-HCoV-OC43 functions is that the former is additionally dependent
upon TRIM56’s C-terminal portion. I speculate that this might accommodate the different
replication strategies between flaviviruses and coronaviruses. Given that the C-terminal
region mediates the interactions of TRIM56 with STING, N-terminal protease of BVDV,
and TRIF (34,39,58), protein-protein interactions via the C-terminal portion may
participate in TRIM56’s antiviral actions against YFV and DENV2. Besides facilitating
presentation of specific substrate to E2 conjugating enzyme, TRIM56’s C-terminal part
may form a complex with flaviviral protein(s) and/or perhaps flavivirus-specific host
factors in the cytoplasm, in ways that hinder viral RNA replication. I favor the notion that
host factors are likely targeted by TRIM56 given that we did not find any BVDV
replicase proteins to interact with TRIM56 in a previous study (34). In contrast to the
proposed canonical TRIM E3 ligase model in which the RING domain and C-terminal
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portion work in concert (29,65), the E3 ligase activity as the sole prerequisite for
TRIM56’s anti-HCoV-OC43 effect might suggest a reliance on some other co-factors to
accomplish substrate presentation in lieu of TRIM56’s C-terminal portion, which will
require further investigation. Obviously, identifying the interaction partners of TRIM56
holds the key to understanding the exact antiviral mechanisms. Studies to this end are
underway in our laboratory.
Possible Molecular Mechanisms Underlying Which C-terminal End of TRIM56
Undermines Influenza Virus RNA Replication
In this body of work, I have demonstrated that TRIM56 compromised propagation of
both influenza A and B viruses by suppressing viral RNA replication (Figures 4-1, 4-2,
4-6 and 4-7), which only requires TRIM56’s C-terminal 63 residues (Figures 4-3 and 44). Moreover, expression of this short C-terminal segment (CTT135 or CTT63) restricts
influenza viruses as effectively as WT TRIM56 (Figure 4-5). In line with its function in
curbing influenza virus RNA replication, which takes place in the nucleus, I found that a
fraction of TRIM56 moved into the nucleus after influenza virus infection (Figure 4-8).
This is also true for CTT63. These findings provide insights into the mechanisms by
which TRIM56 curbs these medically-important negative-strand RNA viruses.
Precisely how the C-terminal tail portion of TRIM56 impedes influenza viral RNA
synthesis is unclear. The C-terminal region of TRIM56 has been shown to interact with
viral and cellular proteins imparting various biological functions, as exemplified by the
TRIM56 association with the N-terminal protease of BVDV (34), TRIF (39), and STING
(58). In light of this, TRIM56 may associate with a component(s) of viral RNP or a
proviral host factor(s) recruited to the RNP complex, interfering with the partner’s role in
viral RNA synthesis. This notion, to some extent, is supported by the confocal data
(Figure 4-8), which suggest co-localization of TRIM56 with NP or M proteins after IAV
infection. In addition, in co-IP assays performed in HEK293-TLR3-YFP cells
overexpressing Flag-HA-tagged TRIM56 (293-T3Y-FH-TRIM56), and I observed that
TRIM56 formed a complex with NP during IAV infection (data not shown). More
experiments are still required to confirm the TRIM56-NP interaction and determine its
biological consequences.
However, another possibility is that TRIM56 interacts with influenza viral RNAs,
altering their incorporation into the viral transcription/replication complex and/or their
stability. Though TRIM56 was not previously identified in influenza virus particles (89),
the possibility of TRIM56 associating with mRNAs of influenza virus or proviral cellular
factors and regulating their translation also cannot be ruled out. Intriguingly, the Cterminal region of TRIM56 (residues 521-748, see Figures 4-5A and 4-9) exhibits
sequence homology with NHL repeats based on a search of the NCBI conserved domain
database. Sequence alignment of TRIM56 with several well-characterized TRIM-NHL
proteins, TRIM2, TRIM3, TRIM32 and TRIM71, also showed conservation on numerous
consensus residues shaping the NHL repeats (Figure 4-9) (75,76). The NHL repeats fold
into a barrel-like β-propeller structure, whose partial surface is positively charged and
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could directly interact with the phosphate backbone of RNA, which is negatively
charged. As an example, TRIM71 can associate with miRNAs and mRNAs and regulate
translation and mRNA metabolism (90). Obviously, further investigation is required to
elucidate how TRIM56 hinders influenza virus RNA synthesis, knowledge of which will
provide new insights into factors and molecular interactions controlling this vital step in
influenza virus life cycle.
Dissect the Molecular Mechanisms Dictating TRIM56-mediated Positive Regulation
of the TLR3 Signaling Pathway
In this body of work, I studied the TRIM56 molecular determinants that govern the
positive regulation of TLR3-mediated IRF3 and NF-κB activation. Confirming our
previous finding that TRIM56 formed a complex with TRIF in an overexpression setting
(39), I found that an association of endogenous TRIM56 and TRIF proteins occurs at an
early stage after TLR3 engagement (Figures 5-1), prior to dsRNA-induced ISG56
expression through this pathway. Detailed domain mapping suggests that TRIM56’s
coiled-coil domain and aa 431-610 were required for augumentation of TLR3 signaling
(Figures 5-2 and 5-3). Further, three conserved, putative phosphorylation sites S471,
S475 and S710 were found to be important for up-regulation of TLR3-mediated signaling
(Figure 5-4). Concordant with this, I demonstrated that the putative phosphorylation sites
S471, S475 and S710 as well as the coiled-coil domain are essential for TLR3-mediated
establishment of an antiviral state (Figure 5-5). Given that the coiled-coil domain confers
TRIMs with scaffolding function and that post-translational modification, such as
phosphorylation, play an important role in regulating protein function (34,66,85), our
data suggest that further studies of TRIM56’s scaffolding function and phosphorylation
status at S471, S475 and S710 after TLR3 engagement are important to better understand
the precise molecular mechanisms by which TRIM56 positively regulateTLR3 signaling.
Although TLR3 contributes to sensing viral invasion and facilitating the
establishment of an antiviral state during certain viral infections, excessive and
unregulated immune signaling through this PRR may lead to overwhelmingly harmful
inflammatory responses detrimental to the host (4,84). I have demonstrated that TRIM56
promotes TLR3-mediated NF-κB activation, supporting that TRIM56 might play a role in
inflammatory cytokine/chemokine responses. It would be interesting to examine whether
TRIM56-regulated TLR3 signaling leads to heightened up-regulation of proinflammatory cytokines/chemokines, which are NF-κB-dependent. Another intriguing
question is how host cells tune down TRIM56-promoted TLR3 signaling after PAMPs
have been sensed and this pathway has been activation. Indeed, the dynamic interaction
between endogenous TRIM56 and TRIF protein (Figure 5-1C) suggests the association
between TRIM56 and the TLR3 adaptor protein may be tightly regulated.
To further investigate exactly how the scaffolding function conferred on TRIM56 by
its coiled-coil domain contributes to positive regulation of TLR3 signaling, it would be
worthwhile to correlate TRIM56’s scaffolding function with its ability to promote the
TLR3 signaling. This aspect could be examined by determining whether the ΔCoiled-coil
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mutant that fails to promote TLR3 signaling loses the scaffolding function. To this end, I
have performed native PAGE and subsequent immunoblot analysis demonstrating that
WT TRIM56 molecules self-associate to form homodimers but the ΔCoiled-coil mutant
failed to do so (data not shown). Moreover, to directly demonstrate that the ΔCoiled-coil
mutant loses the ability to associate with each other, V5-tagged, WT TRIM56 or
ΔCoiled-coil mutant will be co-transfected into HEK293 cells with GFP-tagged WT
TRIM56, followed by IP using anti-V5 and immunoblot analysis for GFP-tagged WT
TRIM56. Further, key residues in TRIM56’s coiled-coil domain, which are critical for
self-association or oligomerization, should be identified and tested for their necessity for
TRIM56-mediated augmentation of TLR3 signaling. Recent crystallographic and
biochemical analyses have demonstrated that L252 and E256 in the TRIM25 coiled-coil
domain are two important residues stabilizing the elongated antiparallel hairpin dimer
formed by the coiled-coil domains (66). Interestingly, that leucine residue is well
conserved among different TRIMs including TRIM56, in which it is at 266 position
(L266). In the future, it will be interesting to determine the effect of L266 mutation on
TRIM56 dimerization and TRIM56-mediated enhancement of TLR3 signaling..
My data suggest that putative phosphorylations on S471, S475 and S710 may be
important for the ability of TRIM56 to promote TLR3 signaling. Obviously, directly
examining this post-translational modification at these residues is warranted. Along this
line, our attempts to detect phosphorylation of TRIM56 at S471, S475 and S710
following TLR3 engagement by performing IP using anti-TRIM56 antibody followed by
immunoblot analysis using anti-phosphoserine antibody have thus far failed, due to the
poor specificity and sensitivity of the available anti-phosphoserine antibodies. To solve
this problem, we have custom-made phospho-specific antibody recognizing p-S471 or pS475 and experiments with these antibodies are under way.
Conclusion
I unveiled the spectrum and specificity of the antiviral activities of TRIM56 against
distinct positive-strand RNA viruses such as yellow fever and dengue viruses as well as
human coronavirus-OC43, broadening the scope of the roles this TRIM plays in antiviral
immunity (Figures 3-1 and 3-2). Equally important, I showed that TRIM56
accommodates these previously unrecognized antiviral functions via overlapping and
distinct molecular determinants, which dictate shared and disparate antiviral actions
(Figures 3-6, 3-7 and 3-9). These new revelations provide novel insights into the detailed
antiviral mechanisms of TRIM56 (Figure 3-10) and raise the possibility of targeting this
TRIM for development of broad antivirals.
Furthermore, I identified TRIM56 as an intrinsic cellular restriction factor of influenza
A and B viruses (Figures 4-1 and 4-2) and described a novel, E3 ligase-independent
antiviral mechanism that targets influenza viral RNA synthesis (Figures 4-3 through 4-7).
Our data delineate novel antiviral properties of TRIM56 against orthomyxoviruses and
may open new avenues to developing influenza antivirals.
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Last but not least, I confirmed that TRIM56 is a positive regulator of TLR3-mediated
NF-κB signaling (Figure 5-1) and demonstrated that a large C-terminal portion and the
coiled-coil domain of TRIM56 are both essential for promoting TLR3 signaling
(Figures 5-2 and 5-3). Further, I demonstrated a requirement for 3 putative
phosphorylation sites, i.e., S471, S475 and S710 for TRIM56-mediated augmentation of
TLR3 signaling. S710 may be an important binding site for TRIM56-TRIF interaction
(Figures 5-4 through 5-6), or phosphorylation at this residue is critical for maintaining
the proper conformation of TRIM56 C-terminus. Furthermore, I demonstrated that
TRIM56’s coiled-coil domain is indispensable for TLR3-mediated establishment of an
antiviral state (Figure 5-5), confirming the signaling data. Together, my data revealed
novel insights into the mechanism dictating TRIM56’s augmentation of TLR3-dependent
antiviral response and highlighted role for TRIM56 scaffolding and phosphorylation in
positive-regulation of TLR3 signaling.
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